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ABSTRACT 
 
Influenza A virus (IAV) is the leading cause of seasonal flu epidemics. The Centers for 
Disease Control and Prevention (CDC) estimates that influenza viral infections cause 12,000 to 
79,000 annual deaths in the United States. IAV also causes global flu pandemics, such as the 
1918 flu pandemic (a. k. a. Spanish flu), which was responsible for an estimated 50 million 
deaths. Despite its importance, molecular determinants of the high virulence of 1918 IAV remain 
elusive. 
The virulence of influenza virus is a multigenic trait, which is dependent on the 
interactions between several viral and host factors. Of the viral factors, nonstructural protein 1 
(NS1) is considered particularly important because it counteracts the host antiviral immune 
system. NS1 comprises an RNA binding domain (RBD), an effector domain (ED), and a long-
disordered C-terminal tail (CTT). RBD binds viral double-stranded RNA (dsRNA), sequestering 
the viral RNA from the host innate immune response. The ED and CTT bind a wide range of 
host proteins, including 30 kDa subunit of cleavage and polyadenylation specificity factor 
(CPSF30), tripartite motif-containing proteins (TRIM), and polyadenylate-binding protein II 
(PABII), suppressing type-I interferon (IFN) expression. Recently, NS1 was also found to 
activate phosphatidylinositol 3-kinase (PI3K) and subsequently suppresses cellular apoptosis, 
resulting in enhanced viral replication. The intrinsically disordered CTT in NS1 contains several 
short linear motifs that interact with diverse host proteins.  
One of the most notable functional differences between the 1918 NS1 and those of other 
human IAVs is that the 1918 NS1 CTT contains a Thr to Pro mutation at residue 215 (T215P). 
This mutation enables the interaction between 1918 NS1 and members of the host CT10 
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regulator of kinase (CRK) protein family, which is not observed in other NS1 proteins. CRKs are 
signaling adaptor proteins, which are involved in a variety of cellular signaling pathways 
involved in cell migration, immune response, cancer metastasis and invasion. Therefore, 1918 
NS1 interferes with the interactions between CRK and its cellular binding partners such as c-Jun 
N-terminal kinase (JNK) and Abelson (ABL) tyrosine kinase, resulting in an enhanced 
cytopathogenic effect. Moreover, recent studies have indicated that hijacked CRK plays an 
important role in hyperactivation of PI3K by 1918 NS1. However, the mechanism of how 1918 
NS1 exploits hijacked CRK to hyperactivate PI3K remains to be determined. 
To reveal the molecular mechanism by which 1918 NS1 hyperactivates PI3K using CRK, 
this dissertation aims to (1) characterize the structures of 1918 NS1 and its complex with PI3K 
and CRK using nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography, (2) 
elucidate the thermodynamic and kinetic mechanisms of its binary (1918 NS1-CRK and 1918 
NS1-PI3K) and ternary interactions (CRK-1918 NS1-PI3K), using fluorescence, isothermal 
titration calorimetry (ITC), and bio-layer interferometry (BLI). Moreover, CRK proteins are 
involved in human cancer metastasis and invasion. The interaction between CRK and BCR-
ABL, an oncogenic mutant of ABL kinase, plays important roles in chronic myeloid leukemia, 
suggesting that inhibiting the interaction of CRK with BCR-ABL might attenuate cancer 
metastasis. This dissertation demonstrates a rational strategy for the development of potent CRK 
inhibitors using a CRK-binding motif contained in 1918 NS1. The designed peptide binds to the 
N-terminal Src-homology-3 (nSH3) domain of CRK with a 10 nM affinity. An in vitro 
biochemical assay demonstrated that the peptide effectively inhibits the phosphorylation of CRK 
by ABL kinase.  
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NOMENCLATURE 
 
IAV Influenza A virus  
CDC Centers for Disease Control and Prevention  
NS1 nonstructural protein 1 
CTT C-terminal tail  
RBD RNA binding domain 
ED effector domain 
CTT C-terminal tail  
dsRNA double stranded RNA  
CPSF30 30 kDa subunit of cleavage and polyadenylation specificity factor 
TRIM tripartite motif-containing proteins  
PABII polyadenylate-binding protein II  
IFN interferon 
RIG-I Retinoic acid-inducible gene I 
TLRs toll-like receptors 
PI3K phosphatidylinositol 3-kinase 
CRK CT 10 regulator of kinase  
CML chronic myeloid leukemia 
JNK c-Jun N-terminal kinase   
ABL Abelson tyrosine kinase 
HA hemagglutinin  
NA neuraminidase 
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PB1 polymerase basic protein 1 
PB2 polymerase basic protein 2  
PB1-F2 polymerase basic protein 1-F2  
PA polymerase acidic protein 
M1 Matrix protein 1 
M2 Matrix protein 2 
NEP nuclear export protein  
PDZ Post-synaptic density 95, Drosophila Discs-large, and Zonula occludens-1 
PDZ proteins PDZ domain-containing proteins  
SH3 Src homology 3 
PRM proline rich motif  
CPMG Carr-Purcell-Meiboom-Gill  
RD relaxation dispersion 
CSP chemical shift perturbation 
IDP intrinsically disordered protein 
IDR intrinsically disordered regions  
MD molecular dynamics 
PPI protein-protein interaction 
PPII type-2 polyproline 2  
PKR Protein kinase R  
RNaseL Ribonuclease L  
PRRs pathogen recognition receptors 
caspases  cysteine-dependent aspartate-directed proteases  
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PBM   PDZ-ligand binding motif  
PKB   protein kinase B 
mTORC2  mammalian target of rapamycin complex 2  
eIF4E   eukaryotic translation initiation factor 4E 
GAP   GTPase-activating protein domain 
ABD   adaptor binding domain   
RTKs   receptor tyrosine kinases  
GPCR   guanine nucleotide–binding protein–coupled receptors  
PIP2   phosphatidylinositol (3,4)-bisphosphate  
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CHAPTER I  
INTRODUCTION 
 
Influenza A virus 
Influenza, also known as the flu, is an infectious disease caused by influenza viruses. 
Influenza viruses belong to the Orthomyxoviridae family [1]. They usually cause mild to severe 
respiratory symptoms in humans and animals [2]. They are classified into four groups: A, B, C 
and D. Influenza A and B viruses cause seasonal epidemics every year, which annually result in 
150,000 hospitalizations and 30,000-40,000 deaths in the United States [3]. Influenza A viruses 
(IAVs) also occasionally cause influenza pandemics, and result in much higher mortality and 
morbidity [1, 4].  
 
The structure and genome of the IAV 
IAVs are enveloped viruses with segmented, negative-sense single-stranded RNA 
genomes [5]. The genome of IAVs consists of eight RNA segments, which encode 11 proteins 
including glycoproteins hemagglutinin (HA) and neuraminidase (NA), the viral RNA 
polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2), polymerase basic protein 1-
F2 (PB1-F2), polymerase acidic protein (PA), Matrix protein 1 (M1), a proton-selective ion 
channel Matrix protein 2 (M2), nonstructural protein 1 (NS1), and NS2/nuclear export protein 
(NEP) [6, 7] (Fig.1).  
M1 protein forms the shell of the virus envelope beneath the lipid layer derived from host 
cell membrane. HA, NA, M2 protein are embedded in the viral envelope. NP binds to viral RNA 
to form viral ribonucleoproteins (RNPs), which associate with RNA polymerases. Based on the 
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antigenicity of HA and NA, IAVs are divided into different subtypes. There are 18 variants of 
hemagglutinin (H1-H18) and 11 different neuraminidase subtypes (N1-N11) [8].  
 
 
Figure 1. The virus particle and genome of the influenza A virus. The two surface proteins, 
HA and NA, and the M2 ion-channel protein are shown as blue, orange and purple respectively. 
M1 protein (green) forms a layer of proteins on the viral envelope beneath the lipid membrane 
(black). The 8 RNA segments are shown as rectangles in different colors.  
 
Influenza epidemics and pandemics 
IAVs constantly circulate and mutate in humans. Infection with IAVs induces protective 
immunity, such as antibodies against viral HA and NA [8]. The mutations in the antigenic sites 
on viral glycoproteins, called antigenic drift, create new virus strains that are not effectively 
neutralized by host immunity, which is often the cause of seasonal epidemics [5].  
IAVs infect a wide range of hosts, including birds, pigs, horses, and humans [9]. Wild 
birds are known to be the natural reservoir of IAVs [9, 10]. The broad spectrum of hosts and the 
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segmented nature of the virus give IAVs the opportunity to exchange genetic material in co-
infected host cells [11, 12]. This process is called reassortment. The reassortment between 
mammalian and avian influenza viruses in particular can result in swapping of their HA and/or 
NA segments, known as antigenic shift. Due to the lack of human immunity to these new 
viruses, antigenic shift can lead to global pandemics [4, 13]. There have been four influenza 
pandemics since the last century [14]. Of those, the 1918 IAV (also known as Spanish flu virus) 
infected one third of world population and caused the death of more than 40 million people [4]. 
Other pandemics that have emerged include the Asian flu (1957-1958), Hong Kong flu (1968-
1969), and the recent pandemic flu occurred in 2009-2010 [4, 15].  
 
The replication cycle of IAVs  
Virus attachment to host cells is initiated by the binding of HA to sialic acid on the cell 
surface [5]. The viral particles are then internalized through receptor-mediated endocytosis [13]. 
In the endosomes, the low pH environment triggers a conformational change in HA and 
dissociation of the M1 protein, leading to the uncoating of IAV and release of the viral 
ribonucleoprotein (vRNP) complexes containing the genomic RNA segments bound to viral 
RNA polymerase and NP [16]. In the cytoplasm, the nuclear localization signals of vRNP bind to 
the nuclear import factor, importin α, translocating the vRNP complexes from the cytoplasm to 
the nucleus [5]. In the nucleus, vRNP mediates the replication and transcription of the viral 
genome. Newly synthesized vRNPs are exported to the cytoplasm by NS2, where cytoplasmic 
ribosomes translate viral mRNA into viral proteins [17]. Virus particles then assemble at the cell 
membrane. Upon the cleavage of sialic acid from the glycoproteins by NA, the viral particles are 
released from the infected cells [17, 18].  
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The host innate immune signaling against IAVs 
The human innate immune response provides the first line of defense against IAV 
infections, while adaptive immunity including antigen-specific memory cells and antibodies are 
responsible for clearing viruses in the later stages of infection [19, 20]. The mucus layer and 
epithelial cells are the first host barrier to IAVs. In addition, certain characteristics of viral RNA, 
such as double-stranded RNA (dsRNA) and the 5’triphosphate group, are sensed by pathogen 
recognition receptors (PRRs) during IAV infection, stimulating the production of antiviral 
agents, such as type I interferons (IFNs), pro-inflammatory cytokines and chemokines [20, 21] . 
IFNs induce an antiviral state in host cells to restrict viral replication, while inflammatory 
cytokines and chemokines direct immune cells to infection sites and mediate viral clearance 
(Fig.2) [20, 22].  
Retinoic acid-inducible gene I (RIG-I) and toll-like receptors (TLRs) are the most 
thoroughly studied PRRs [20]. RIG-I recognize viral RNA in the cytoplasm, and recruits TRIM-
containing protein 25 (TRIM25) upon binding to RNA. TRIM25 is a RING-type E3 ligase, 
which ubiquitinates RIG-I [23]. The ubiquitination of RIG-I activates the mitochondrial antiviral 
signaling protein (MAVS), leading to the initial activation of interferon regulatory factor 3 (IRF-
3), IRF7 and nuclear factor NF-κB. The activation of transcription factor IRF-3 and NF-κB 
initiates the expression of interferon-β (IFN-β) and pro-inflammatory cytokines [20]. Toll-like 
receptors (TLRs) are PRRs that sense viral RNA in the endosomes and lysosomes and stimulates 
the expression of cytokines by activating IRF-3, IRF7 and nuclear factor NF-κB [20, 24]. 
 Secreted IFN-β binds to type I interferon receptors and stimulates transcription of a 
variety of antiviral acting genes to restrict different steps of the IAV replication cycle and prime 
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the adaptive immune system [25]. Protein kinase R (PKR) is an interferon-induced 
serine/threonine kinase that dimerizes upon binding to viral RNA. The dimerization of PKR 
leads to its autophosphorylation and activation [25]. Activated PKR induces the phosphorylation 
of the eukaryotic initiation factor 2α (eIF2α), which in turn suppresses the translation of cellular 
and viral proteins [26]. 2'-5'-oligoadenylate synthetase (2’,5’-OAS) is also an interferon-induced 
antiviral protein. 2’,5’-OAS senses viral RNA and synthesizes 2’-5’-oligoadenylates from ATP, 
which activates Ribonuclease L (RNaseL) [27]. Activated RNaseL degrades viral RNA and 
activates PRRs [28]. In addition to their intracellular antiviral mechanisms, secreted IFNs and 
other cytokines also activate extracellular antiviral cell death-inducing systems. For example, 
type-I IFN production stimulates the expression of Fas ligand (FasL), which binds to the death 
receptor Fas activating cysteine-dependent aspartate-directed proteases (caspases) [25]. The 
activation of caspases leads to the induction of cell apoptosis, restricting virus spread by 
removing locations for virus propagation [29].  
 
Figure 2. Schematic diagram of the host cell immune signaling induced by viral RNA.  
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Virulence determinants of 1918 IAV 
 The genome of 1918 IAV was completely sequenced in 2005 [4]. The resurrected 1918 
IAV showed extremely high virulence in mice, ferrets, and macaques [30-32]. It was suggested 
that the high virulence of the 1918 IAV was associated with HA, NA, RNA Polymerase and NS1 
[33, 34]. NS1 gene of 1918 IAV showed a high activity in antagonizing the expression of IFN-
regulated genes [4]. HA plays a critical role in receptor binding specificity and efficient 
transmission of the 1918 IAV [35, 36]. RNA polymerase complex plays an important role in 
promoting efficient spread of 1918 IAV to the lower respiratory tract [34]. PB2 was also required 
for the efficient transmission of the 1918 IAV [37]. 
 
NS1 of IAVs 
The innate immune response is a critical component of host barrier for IAVs [6, 14, 38]. 
However, IAVs utilize NS1 to manipulate cellular machinery to antagonize the innate immune 
response and promote virus replication [39-42].  
 
The structure of NS1  
NS1 is a virulence factor containing 230-237 amino acids, depending on IAV strains 
[43]. NS1 consists of an RNA binding domain (RBD) in the N-terminal region, an effector 
domain (ED) and an intrinsically disordered C-terminal tail (CTT) (Fig.3) [44]. The structures of 
the RBD and ED are well conserved among different strains [45]. The RBD consists of three α-
helices and functions as dimer. The ED consists of seven β-strands and three α-helices (Fig.3A) 
[44, 46].  
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Figure 3. The structure and domain organization of NS1. (A) The structure of NS1 from 
H5N1 IAV (A/Vietnam/1203/2004). The α-helices are shown in red and the β-strands are shown 
in green, while the loops are shown in gray. (B) The domain organization and binding partners of 
the 1918 IAV NS1. RBD binds to viral dsRNA. ED interacts with PI3K, CPSF30 and TRIM. 
The CTT binds to CRK, PDZ proteins and PABII. 
 
The function of NS1  
The RBD of NS1 binds to dsRNA and sequesters it from recognition by the host immune 
system (Fig.3) [47]. It was also found that RBD is associated with the ability of NS1 to recruit 
ribosomes to target mRNAs and stimulate their translation [48]. The ED targets multiple host 
proteins including phosphatidylinositol 3-kinase (PI3K), the 30 kDa subunit of the cleavage and 
the polyadenylation specificity factor (CPSF30) and the Tripartite motif 25 (TRIM25) [49-51]. 
PI3K is a lipid kinase, which plays key roles in the regulation of cell cycle progression and cell 
apoptosis [52]. The activity of PI3K is normally regulated by extracellular stimulation. However, 
PI3K is activated in an unregulated fashion by NS1 binding [39, 53]. The activated PI3K inhibits 
virus-induced apoptosis and promotes virus replication in infected cells [39, 54]. CPSF30 is an 
important component of the 3’end processing machinery for cellular pre-mRNAs [55]. The 
 8 
 
hijacking of CPSF30 by NS1 selectively inhibits the processing and nuclear export of cellular 
pre-mRNA processing, but doesn’t affect viral mRNA [56]. It has been shown that the ED of 
NS1 binds to TRIM25 and that this interaction suppresses TRIM25 substrate ubiquitination and 
inhibits the subsequent activation of the immune response [49].  
The CTT of NS1 is a structurally disordered region which contains several linear motifs 
that interact with different host proteins, such as CT-10 regulator of kinase (CRK) proteins, Post-
synaptic density 95, Drosophila Discs-large, and Zonula occludens-1 (PDZ) domain-containing 
proteins (PDZ proteins) and poly(A)‐binding protein II (PABII) [57-59]. It was shown that a 
proline rich motif (PRM) exists in the NS1 of certain avian virus strains including the 1918 IAV, 
but not in other human IAVs [59]. The PRM of NS1 binds to CRK proteins [51, 59]. The 
hijacking of CRK proteins by NS1 interferes with cell signaling mediated by c-Jun N-terminal 
kinase (JNK) and Abelson (ABL) kinase [39, 51, 60, 61]. These result in the inhibition of INF 
production and increased viral replication [39, 62, 63]. In addition, hijacking of CRK by NS1 
also hyperactivates PI3K which further promotes viral replication, although the underlying 
mechanism is unclear [64]. The CTT of NS1 also contains a PDZ-ligand binding motif (PBM) 
that associates with cellular PDZ proteins such as Scribble (Scrib) and Discs large 1 (Dlg1) [58, 
65]. These interactions disrupt cellular tight junctions which are important for allowing viral 
particles to cross the epithelial barrier [58]. NS1 also binds to PABII of the cellular 3′‐end 
processing machinery, interfering with cellular mRNA processing [57]. 
In this Dissertation, I focus on the interactions of NS1 of 1918 IAV (1918 NS1) with 
PI3K and CRK. Therefore, the following sections of this chapter will be dedicated to a review of 
the cellular function and structure of these two host proteins, and their interaction with NS1.  
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The interaction between NS1 and PI3K 
The cellular function of PI3K 
PI3Ks are a family of lipid kinases which phosphorylate the hydroxyl group of the 
inositol ring of phosphatidylinositol (3,4)-bisphosphate (PIP2) lipids and convert it to 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [66] (Fig. 4). PIP3 acts as a second messenger 
and binds to the pleckstrin homology (PH) domain of protein kinase B (PKB), also known as Akt 
[67]. Akt is subsequently recruited to the cell inner membrane and is phosphorylated by PDK1 
on T308 of its activation loop and by the mammalian target of rapamycin complex 2 (mTORC2) 
on Ser 473 [67]. Activated Akt then phosphorylates and activates downstream effector proteins, 
such as mammalian target of rapamycin complex 1 (mTORC1) [68]. Activation of mTORC1 
enhances protein synthesis by activating eukaryotic translation initiation factor 4E, also known 
as eIF4E [69]. In another pathway, activated Akt phosphorylates the forkhead box O 
transcription factor (FOXO) and subsequently inhibits the activity of FOXO by preventing its 
nuclear translocation [68]. FOXO plays a pivotal role in the promotion of cell apoptosis, 
inhibition of cell growth and suppression of tumor growth [61, 70]. FOXO also induces 
expression of pro-apoptotic proteins and stimulates the expression of ligands that bind to death 
receptors including Fas [71]. This triggers activation of caspases and the subsequent cell 
apoptosis [72]. Activated Akt also directly phosphorylates apoptotic protease caspase-9 which 
inhibits its protease activity [73]. Hence, activation of Akt by PI3K results in the inhibition of 
cell apoptosis and the promotion of cell growth [52].  
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The structural components of PI3K 
PI3K family is divided into 3 distinct classes: I, II and III. PI3K is a heterodimer 
consisting of a regulatory subunit (typically p85 α or β) and a catalytic subunit (p110α, β, δ) [54]. 
Class I PI3Ks are further grouped into Class 1A and Class 1B based on the catalytic subunit [66]. 
Class 1A PI3Ks contain a p110α, p110β, or p110δ subunit, while class 1B contains p110γ [74]. 
Here we only focus on Class 1A PI3K. The PI3Ks in this dissertation mean Class 1A PI3Ks if 
not otherwise indicated. 
The p85 regulatory subunit contains an N-terminal Src homology 3 (SH3) domain, a 
GTPase-activating protein domain (GAP), followed by two SH2 domains (nSH2 and cSH2) 
linked by an intervening inter-SH2 domain (iSH2) [75] (Fig.4). The p110 catalytic subunit 
consists of an N-terminal adaptor binding domain (ABD), a Ras binding domain (RBD), a C2 
domain, a helical domain, and C-terminal kinase domain [75]. The activity of p110 is normally 
regulated by p85. Structural studies show that the two SH2 domains and the coiled-coil iSH2 
domain are responsible for the inhibitory effect of p85 on p110 [57].  
 
The regulation of PI3K activity in host cells 
In the cytosol, the activity of p110 is auto-inhibited by p85 (Fig.4). Structural studies 
show that the nSH2 and cSH2 domains of p85 form a ‘clamp’ that holds p110 in an inhibited 
conformation (Fig.4B) [75]. In the inhibited state, the entry of the substrate to the active site of 
p110 is restricted, which results in the loss of PI3K activity.  
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Figure 4. The activity of PI3K is regulated by regulatory subunit. (A) The domain 
organization of PI3K. The nSH2, iSH2 and cSH2 domains are highlighted with purple, orange 
and cyan color. (B) The activity of PI3K is auto-inhibited by the nSH2 and cSH2 domains of 
p85. (C) Binding of the phosphorylated tyrosine motif to nSH2 relieves the inhibitory effect of 
p85 on p110. 
 
PI3K can be activated by receptor tyrosine kinases (RTKs) or heterotrimeric guanine 
nucleotide–binding protein (G protein)–coupled receptors (GPCRs) on cell membranes (Fig.5) 
[75]. The binding of extracellular stimuli, such as epidermal growth factor (EGF), to RTKs 
induces their dimerization and subsequent phosphorylation [67]. The phosphorylated tyrosine 
motifs on the RTKs bind to the two SH2 domains of p85, which relieves their inhibitory effect 
on p110 (Fig.4C) [76]. Activated PI3K further converts PIP2 to PIP3. PIP3 then activates Akt and 
its downstream effector proteins [52]. The p110β isotypes are also activated by the Gβγ 
heterodimers of GPCRs, resulting in the activation of Akt [75]. 
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Figure 5. The cellular function of PI3K. Stimulation of EGF induces dimerization and 
phosphorylation of EGFR. The phosphorylated tyrosine motif on EGFR then binds to p85 of 
PI3K, and relieves its inhibition of p110. The activated PI3K then phosphorylates PIP2 to PIP3 
and PIP3 activates Akt. Activated Akt triggers a downstream signaling cascade which modulates 
cell survival, cell cycle progression, growth and translation. 
 
Hijacking PI3K by NS1 of IAVs 
Ludwig, et al. discovered that PI3K is activated by NS1 during IAV infection, which is 
important for efficient virus propagation [77]. The activation of PI3K by NS1 not only supports 
endocytotic uptake of the viral particles in the early stages of virus infection, but also suppress 
apoptotic signaling of infected cells in the later stages of the viral replication cycle by activating 
Akt [77, 78]. Both of these effects are important for efficient viral propagation. Strain-specific 
effects of NS1-induced PI3K activation on viral replication were also observed in several studies 
[79, 80]. Additional studies showed that NS1 preferentially interacts with p85β, but not p85α 
 13 
 
[64]. Studies by Hale et al. showed that the binding of NS1 to p85β is primarily mediated by the 
ED of NS1 and the iSH2 domain of p85β, although weak interactions between NS1 with a SH3 
domain and the cSH2 domain of p85 were also observed in a different study [50, 81]. These 
studies suggested that NS1 occupies the same position as it was shown for nSH2 in the 
autoinhibitory conformation (Fig.4B, Fig.6A). The binding of NS1 to the iSH2 domain of p85 
prevents nSH2 from p110 and releases its inhibition, which explains the mechanism of PI3K 
activation by NS1 [61]. 
 
 
Figure 6. The activation of PI3K by NS1. (A) The binding of NS1 to p85 prevents the nSH2 
domain from rebinding p110. (B) The binding of NS1 to p85 relieves the inhibitory effect of p85 
on p110 and activates PI3K in an unregulated fashion. Activated PI3K eventually leads to the 
inhibition of cell apoptosis, which gives virus enough time to replicate. 
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The hijacking of CRK proteins by NS1 
The cellular function and structural components of CRK proteins 
CRK proteins are a family of signaling adaptor proteins that utilize their multiple protein-
binding modules to spatially and temporally regulate a variety of cell signaling processes, such 
as cell migration, proliferation, bacterial infection, cancer metastasis and invasion [82-84].  
 
 
Figure 7. The schematic representation of CRK proteins. The SH2 domain binds to the 
phosphorylated tyrosine motif pYxxP, while the nSH3 domain binds to the proline rich motif 
with a consensus sequence of PxLPxK where ‘x’ represents any amino acid. 
 
CRK was originally identified as an oncogene product of chicken tumor 10 (CT10) 
retroviruses [85]. The family of human CRK proteins includes CRKI, CRKII and CRK like 
(CRKL) (Fig.7) [86]. Both CRKII and CRKL consist of a SH2 domain, an N-terminal SH3 
(nSH3) domain, and a cSH3 domain [82]. CRKI is an alternatively spliced form of CRKII which 
lacks the cSH3 domain [87]. The sequence of CRKL is highly similar to CRKII [88]. However, 
the SH2 domain of CRKL lacks a flexible loop (DE loop), while the two linkers between each 
domain are longer than in CRKII [88].  
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The multiple binding modules in CRK proteins enable the interactions of CRKs with 
activated receptor proteins and the transduction of specific downstream signaling cascades [82]. 
The SH2 domain of CRK proteins binds to proteins containing a phosphorylated tyrosine motif, 
such as the phosphorylated scaffold proteins p130Cas, paxillin, Gab1 and Gab2, which are the 
downstream effectors of integrin or receptor tyrosine kinases that sense extracellular stimuli, 
such as growth factors and the extracellular matrix (Fig.7) [89]. On the other hand, the nSH3 
domain recognizes PRMs with the PxLPxK core sequence in several proteins, such as the 
guanine nucleotide exchange factor proteins, SOS1 (son of sevenless homolog 1), C3G (guanine 
nucleotide-releasing factor 2), and Dock180 (dedicator of cytokinesis protein 1 180 kDa) [82, 85, 
90]. The assembly of guanine nucleotide exchange factor proteins with scaffold proteins by CRK 
proteins further activates downstream effectors such as GTPases Ras, Rap1, and Rac1, which 
play essential roles in the regulation of cell migration, invasion, proliferation, and membrane 
ruffling [89, 91, 92]. In this way, CRK integrates signals from extracellular stimuli to spatially 
and temporally regulate the activity of GTPases. The cSH3 domain doesn’t bind to the PRMs, 
but is involved in the autoinhibition of CRK [93].  
CRK proteins also regulate the activities of non-receptor tyrosine kinases such as ABL 
kinase, Arg, Src and JNK though binding their PRMs [4, 5]. The biological activity of CRK is 
regulated by the phosphorylation of its tyrosines by ABL kinase [5]. One of the most studied 
phosphorylation sites of CRK is the Y221 of CRKII (or Y207 of CRKL), which is in the linker 
region tethering nSH3 and cSH3 domain [6, 7]. The phosphorylated Y221 binds to the SH2 
domain of CRKII, and induces an “autoinhibition” conformation, in which the interaction 
between SH2 and its ligands is blocked (Fig.8) [94]. There is another phosphorylation site, Y251, 
on the cSH3 domain, phosphorylation of which transactivates ABL [8].  
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Figure 8. The activity of CRK is regulated by phosphorylation of a tyrosine (Y221 of 
CRKII or Y207 of CRKL) in the linker region tethering nSH3 and cSH3 domain. (A) The 
binding of phosphorylated tyrosine in the linker region induces the “autoinhibition” 
conformation (on the right) and blocks the binding of ligands to SH2 domain. B. The binding of 
PRM of ABL to nSH3 domain results in the phosphorylation of CRKII. 
 
Hijacking of CRK by NS1 
 The NS1 protein of the 1918 and many other avian IAVs have the unique capacity to 
bind to the nSH3 domain of CRK with a PRM in their CTT, while NS1 proteins from most of 
human IAVs don’t bind to CRK [6, 95]. The hijacking of CRK by NS1 not only interferes with 
CRK-mediated protein-protein interactions in host cells, but also results in the potentiation of 
NS1-induced PI3K activation [40, 59, 80, 96, 97].   
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Ehrhardt et al. reported that the NS1-CRK interaction suppresses the antiviral-acting 
JNK-ATF2 pathway [40]. The NS1 of avian IAVs also interferes with the interaction between 
CRK and ABL kinase, inhibiting the kinase activity of ABL [62, 98]. Moreover, the binding of 
NS1 to CRK also induces the translocation of CRK into the nucleus, where it interferes with 
protein phosphorylation [96].  
 
 
Figure 9. The NS1-CRK interaction reorganizes the CRK-p85 signaling complex. The PRM 
of p85 binds to CRK in host cells in the absence of NS1 (A). In host cells infected with 1918 or 
Avian strains of IAVs, there are two alternative trimeric complexes: the more stable NS1-bridged 
CRK-NS1-p85 trimeric complex (B) and the less stable p85-bridged CRK-p85-NS1 trimeric 
complex. 
 
It was also discovered that the NS1-CRK interaction hyperactivates PI3K, resulting in 
more efficient viral replication [59]. A weak interaction between CRK and p85 of PI3K, 
mediated by the CRK nSH3 domain and a PRM of p85, has also been observed in several studies 
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(Fig.9A) [99, 100]. A study showed that the NS1-CRK interaction reorganizes the CRK-p85 
binary complex into a NS1-bridged CRK-NS1-p85 trimeric complex [101]. An alternative CRK-
p85-NS1 trimeric complex tethered by p85 also exists, but in a much less stable form due to the 
binding affinity of CRK for the PRM of p85 being much weaker than their affinity for the PRM 
of NS1 [101] (Fig.9B and 9C). As the structure of the CRK-NS1-p85 trimeric complex has not 
yet been determined, the underlying mechanism for the hyperactivation of PI3K by NS1 using 
CRK remains unknown.  
 
The interaction between PRMs and SH3 domain 
 SH3 domains, which are approximately 50-70 amino acids long, are one of the most 
prevalent protein-protein interaction modules found in eukaryotic proteomes [102]. SH3 domains 
are present in a variety of cellular proteins and play significant roles in the regulation of kinase 
activity, cell signal transduction, and membrane localization [103, 104]. SH3 domains usually 
consist of five β-strands and a short 310-helix. The β1-4 strands are connected by three loops, the 
RT, n-Src, and distal loops moving from the N to C-terminal (Fig.10). SH3 domains recognize 
PRMs, which adopt a left-handed type-2 polyproline 2 (PPII) conformation in solution [103]. 
Due to the axial symmetry of PPII helices, PRMs can bind to SH3 domains in two orientations 
[105]. The binding orientation of the PRM and SH3 domain depends on the position of charged 
residues, which are used to divide PRMs into two classes. Class I PRMs have the consensus 
sequence +xxPxxP, while Class II PRMs have sequence xPxxPx+, where ‘+’ means a positively 
charged residue (R or K). For example, the nSH3 domain of CRK proteins recognizes Class II 
PRMs with a consensus sequence of PxLPxK (Fig. 10B) [106]. The canonical core region 
(PxLP) binds to the conserved hydrophobic surface consisting of two small shallow pockets, 
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while the C-terminal lysine forms a salt-bridge network with a cluster of acidic residues in the 
specificity pocket that is formed by residues from the RT and n-Src loops (Fig.10) [107].  
 
 
Figure 10. The interaction between PRMs and SH3 domain. (A) The structure of the CRKII 
nSH3 domain. (B) The structure of the C3G PRM bound to the CRKII nSH3 domain (PDB: 
1CKA) [106]. The protein surface is colored according to electrostatic potential at neutral pH 
from -5 kT (red) to +5kT (blue). The binding mode of class II PRM to SH3 domains is shown at 
the bottom. 
 
The role of CRK in cancers 
 CRK proteins are involved in the induction of malignant phenotypes in various cancer 
cells [108]. The overexpression of CRK and phosphorylated CRK were found in a variety of 
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human cancers, such as lung cancer, breast cancer, glioblastoma, sarcomas, ovarian cancer, and 
hematopoietic cancers [108, 109]. The knockout of CRK by small interfering RNA (siRNA) 
significantly attenuated the invasion and migration of several cancer cell lines [110, 111].  
One of the major binding partners of CRK is ABL kinase [112]. ABL is a type of non-
receptor tyrosine kinase, which plays critical roles in multiple cellular processes regulating cell 
growth, survival, tumor cell invasion and angiogenesis [113]. The translocation of the ABL gene 
from chromosome 9 to chromosome 22 generates BCR-ABL fusion proteins. BCR-ABL has 
constitutive tyrosine kinase activity, which is the hallmark of chronic myeloid leukemia (CML) 
[114].  
ABL binds to CRK using PRMs in its C-terminal disordered region [107]. Upon binding, 
the kinase domain of ABL phosphorylates CRK, which in turn transactivates ABL’s kinase 
activity (Fig.8B) [115]. This interaction is essential for the transformation function of the BCR-
ABL fusion protein in CML [116]. Mutations disrupting the CRK-ABL interaction significantly 
reduce the transformation of CML, indicating that this interaction is a potential drug target for 
the treatment of CML [112].  
 
Objectives of this work 
The replication efficiency of IAVs is an important determinant of its virulence [117]. The 
interactions of NS1 from 1918 IAV with two host proteins, PI3K and CRK, play critical roles in 
promoting the replication of this highly virulent IAV [39, 50, 59, 101]. Despite its importance, 
the molecular mechanism underlying the activation of PI3K by 1918 NS1 using CRK is still 
unclear. Therefore, the major objective of this Disseration is to elucidate the mechanisms by 
which NS1 binds these proteins using a variety of biophysical methods. 
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CRK is a promising drug target for CML [118]. Revealing the molecular determinants of 
the interaction between the PRM of NS1 and the nSH3 domain of CRK will provide insights into 
the design of novel anti-cancer molecules that disrupt the interaction between CRK and ABL. 
Therefore, the second objective of this Dissertation is to develop peptide inhibitors that disrupt 
CRK-ABL interactions based on the binding mechanism of NS1 with CRK. The role of long-
range electrostatics and dynamic disorder in the binding was investigated, and a peptide inhibitor 
was designed with a “proof-of-principle” concept.  
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CHAPTER II 
THE MOLECULAR MECHANISM UNDERLYING THE INTERACTION BETWEEN PRM 
OF NS1 AND N-TERMINAL SH3 DOMAIN OF CRK* 
 
Background 
IAV infects a wide range of avian and mammalian species [119]. While HA protein 
determines virus-host specificity [120], NS1 plays important roles in IAV replication and the 
evasion of antiviral immunity by hijacking and re-wiring host protein-protein interactions [1]. 
Therefore, NS1 has been shown to be a potential antiviral target [56].  
The CTT of NS1 shows the largest amino acid sequence variation among different virus 
strains (Fig.11B) [42]. Recent studies have shown that the CTT of the 1918 NS1 contains a PRM 
that binds to the nSH3 domain of human CRK proteins (CRKI, CRKII, and CRK-L) with 
exceptionally high selectivity [59, 60]. Interestingly, common seasonal IAV NS1 proteins do not 
bind to the nSH3 domain of CRK because of a single amino acid (P215T) replacement in this 
PRM (Fig.17) [59, 60, 62].  
The nSH3 domain of CRK proteins binds to PRMs in a large number of signaling 
proteins, including JNK1 and ABL kinase [88, 115, 121-123]. Therefore, NS1 binding to CRK 
inhibits CRK-JNK1 and CRK-ABL interactions [59, 60, 62], suppressing the host antiviral 
immune response [59]. The binding of NS1 to CRK also results in the hyperactivation of PI3K, 
which eventually leads to the promotion of IAV replication [16]. Despite its critical importance, 
                                                 
* Reproduced with permission from “The Molecular Mechanisms Underlying the Hijack of Host Proteins by the 
1918 Spanish Influenza Virus” by Qingliang Shen, Danyun Zeng, Baoyu Zhao, Veer S. Bhatt, Pingwei Li, and Jae-
Hyun Cho, 2017.  ACS Chem. Biol. 12, 1199-1203. Copyright © 2017 American Chemical Society. 
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the molecular basis by which IAV NS1 hijacks CRK remains to be elucidated.  
 
 
Figure 11. The NS1 of 1918 IAV binds to nSH3 of CRKII. (A) Schematic diagram showing 
the interaction between nSH3 of CRKII and PRM of NS1. B) Sequence alignment of NS1 from 
1918 IAV (A/Brevig Mission/1/18/ H1N1), A/Udorn/72/H3N2 and A/Puerto Rico/8/34/H1N1 
generated by ESPript 3 [124]. Residues that are different with 1918 IAV are colored in red. The 
residues at 215 are highlighted. 
 
In this chapter, we performed X-ray crystallography, NMR relaxation dispersion 
experiment, and fluorescence spectroscopy to determine the structural, kinetic, and 
thermodynamic mechanisms underlying the hijacking of CRKII by 1918 NS1. We observed that 
the interaction between a PRM in NS1 and the N-terminal SH3 domain of CRKII displays 
strikingly rapid kinetics and exceptionally high affinity with 100-fold faster kon and 3300-fold 
lower Kd compared to those for the CRKII−JNK1 interaction. These results provide molecular 
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insight into the mechanism by which 1918 NS1 hijacks CRKII and disrupts its interactions with 
critical cellular signaling proteins. This work has been published in ACS Chemical Biology [6].  
 
Experimental procedures 
Materials  
All protein samples for crystallization, fluorescence and NMR experiments, were 
prepared as described in Chapter II. Synthetic peptides were purchased in a crude form, and 
further purified using reverse-phase high performance liquid chromatography in our laboratory. 
The N- and C-termini of peptides were acetylated and amidated, respectively. The peptide 
concentration was determined by measuring the UV absorption at 280 nm of a single tyrosine at 
the N- or C-terminal ends of the peptides. 
 
Crystallization and structure determination 
4 mM nSH3 was mixed with 5 mM PRMNS1 for the crystallization trials. The sample was 
crystallized by hanging drop vapour diffusion method in 0.1 M sodium acetate (pH 4.6), 30% 
PEG 2000 and 0.2 M ammonium sulfate. A 1.45 Å resolution dataset was collected at 120 K 
using an R-AXIS IV++ image plate detector mounted on a Rigaku MicroMax 007HF X-ray 
generator. The data were processed using iMosflm in the CCP4 package [125]. The structure was 
determined using the nSH3 domain model (PDB ID: 5UL6) as search model using Phenix [126]. 
The NS1 PRM peptide was modeled into the difference map manually in COOT[127] and 
refined with Phenix. The electrostatic potential surface of nSH3 domain was calculated using 
APBS and PDB 2PQR [128-130]. 
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NMR spectroscopy 
All NMR experiments were conducted using protein samples in 20 mM sodium 
phosphate (pH 6.1), 80 mM NaCl, 0.02% sodium azide, 1 mM EDTA, 10 μM DSS (4,4-
dimethyl-4-silapentane-sulfonate), and 10% D2O at 25°C. NMR experiments were performed on 
Bruker Avance 600 MHz and 800 MHz spectrometers equipped with a cryogenic probe. NMR 
spectra were processed with NMRPipe [131] and analyzed with NMRViewJ (One Moon 
Scientific, Inc.) and CARA [132]. The temperatures of NMR sample were calibrated using the 
deuterated methanol-d4 [133].  
 
Binding kinetic measurements 
The association and dissociation rate constants of nSH3-PRM complexes were measured 
using constant relaxation time Carr-Purcell-Meiboom-Gill (CPMG) single quantum relaxation 
dispersion (RD) experiments [134, 135]. The concentration of the nSH3 domain was 200 μM. 
The population ratios of the nSH3-PRMNS1 and nSH3-PRMJNK1 complexes were 93% and 5%, 
respectively, of the entire protein population. In these conditions, the binding processes were in 
intermediate to fast exchange regime in NMR timescales. CPMG-RD experiments were recorded 
with 14-16 different CPMG frequencies (νCPMG), ranging from 50 Hz to 1000 Hz, for each 
dispersion curve. CPMG RD data were acquired at two static magnetic fields (600 MHz and 800 
MHz). R2,eff(νCPMG) were calculated from the peak intensities according to Eq. 1,: 
 
                                               2,
( )1
( ) ln
(0)
CPMG
eff CPMG
relax
I
R
T I


 
  
 
                        Equation 1 
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Trelax is the length of relaxation delay, and I(0) and I(νCPMG) are the intensities of the peak at Trelax 
= 0 ms and 40 ms with a given CPMG frequency, respectively. The uncertainty of R2,eff(νCPMG) 
was estimated by comparing the peak intensities of duplicated spectra of I(0) and I(50 Hz). Using 
these differences in peak intensities, 100 Monte Carlo simulations were performed to measure 
the uncertainty. We assumed that the uncertainty is Gaussian distributed. In our experimental 
conditions, the uncertainties were approximately 5 % of R2,eff(50 Hz). The estimated uncertainty 
was applied to all R2,eff(νCPMG). The CPMG-RD profiles were fitted using the Carver-Richards 
equation (Eq. 2)[136, 137] or the Luz-Meiboom equation (Eq. 3)[138] depending on the 
chemical exchange regime in the NMR timescale[139]. The reported kinetic parameters are the 
results of the global fitting of multiple peaks using either the Carver-Richards or Luz-Meoboom 
equations [136, 140].  
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Fluorescence binding assay 
The dissociation constants (Kd) of nSH3-PRM complexes were measured by monitoring 
the change of tryptophan fluorescence signal. Excitation wavelength was 295 nm. All binding 
assays were performed in a stirred 1-cm path length cuvette using a PTI QM-400 fluorimeter. 
Protein concentration used for the fluorescence-based binding assays was 0.1 μM. The 
measurements were done in 20 mM sodium phosphate (pH 6.1) and 80 mM or 1 M NaCl at  
25 °C. The Kd was calculated by assuming a 1:1 complex, and by the global fitting of the 
repeatedly measured fluorescence intensities to the Eq. 4: 
 
     
 
2
max
[ ] [ ] [ ] [ ] 4[ ][ ]
2[ ]
t t d t t d t t
t
P L K P L K P L
F F
P
      
   
 
 
           Equation 4 
ΔF and ΔFmax are the change and the maximum amplitude of signal change, respectively. Pt is the 
total protein concentration and Lt is the total ligand concentration at each titration point. The 
reported Kd values are the average of 3 or 4 repeated measurements.  
 
Results 
The binding affinity between NS1PRM and nSH3CRKII is exceptionally high 
We synthesized a peptide corresponding to the C-terminal PRM of 1918 NS1 (1918 
PRMNS1) and measured its binding affinity to the nSH3 domain of CRKII (nSH3CRKII) by 
monitoring fluorescence intensity change upon complexation. The Kd of the nSH3
CRKII-PRMNS1 
complex was measured to be 6 nM (Fig.12B and Table 1), which, to our knowledge, is the strongest 
binding observed for any known SH3-ligand interactions. In general,  the Kd for SH3-PRM 
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complexes are in the range of 1 to 10  M [109]. Of note, the nSH3CRKII domain in isolation and 
in the context of full-length CRKII have the similar binding affinities to target proteins [141].  
1918 NS1 has also been shown to interfere with CRKII-JNK1 interaction, resulting in the 
suppression of JNK mediated antiviral activity [40, 63]. Strikingly, we found that the affinity of 
nSH3CRKII-PRMNS1 complex is 3,300-fold higher than that of nSH3CRKII-PRMJNK complex 
(Fig.12C). This result supports that 1918 NS1 inhibits CRK-mediated JNK1 activation resulting 
in impaired interferon (IFN) expression [40, 63]. It has also been reported that the 1918 IAV 
NS1 hijacks CRKII-ABL interaction, which is mediated by the interactions between the 
nSH3CRKII and PRMs of ABL (PRMABL) (Fig.12A) [51] . Previously, we observed that the Kd of 
nSH3CRKII-PRMABL is ~3 M [107]. Hence, the binding affinity between nSH3CRKII and PRMNS1 
is 460-fold higher than that between nSH3CRKII and PRMABL. This surprisingly high affinity will 
enable NS1 to hijack CRKII and interferes with critical protein-protein interactions mediated by 
CRKII in human cells. 
 
Table 1. Thermodynamic and kinetic parameters for the binding  
between the nSH3CRKII and PRMs of NS1 or JNK1.  
 
PRMs Kd (M) kon (108 M-1 s-1)[a]  koff (s-1)[a] 
NS1 0.006  0.002 110  20 66.5  10.1 
JNK1 22.0  1.5 1.06  0.06 2339.5  123.5 
[a] These are the results of a global fit of CPMG-RD data 
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Figure 12. 1918 PRMNS1 binds nSH3CRKII with exceptionally high affinity. (A) Schematic 
diagram showing the hijacking of CRKII-JNK1 and CRKII-ABL interactions by 1918 NS1. 
Binding isotherms of (B) PRMNS1 and (C) PRMJNK1 to the nSH3 domain of CRKII. The 
sequences of PRMs are shown in each panel. The N- or C-terminal Y was incorporated for the 
quantitation of peptides. 
 
The structural basis of the binding specificity of NS1PRM to nSH3CRKII  
It was shown that PRMNS1` binds to nSH3CRKII with high selectivity [60], while PRMs in 
general have low SH3 domain selectivity [142]. To elucidate the structural basis of the 
interaction between the nSH3CRKII domain and PRMNS1, we determined the crystal structure of 
nSH3CRKII-PRMNS1 complex at 1.45 Å resolution (Fig.13A and Table 2). The structure shows 
that PRMNS1 binds to the nSH3 domain in class-II binding mode. NMR chemical shift 
perturbation (CSP) analysis revealed that similar binding surface of the nSH3CRKII is involved in 
the interactions with PRMNS1 in solution (Fig.14). 
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Figure 13. The structural basis of the binding specificity of NS1PRM to nSH3CRKII.  (A) 
Crystal structure of nSH3CRKII-PRMNS1 (PDB ID: 5UL6). The protein surface is colored 
according to electrostatic potential at neutral pH from -5 kT (red) to +5kT (blue). (B) Salt-bridge 
network between three acidic residues of the nSH3 domain and K217 of NS1. (C) Hydrogen 
bonds between E166 of nSH3 and the backbone amides of Q218 and K219 of NS1. Side chains 
are not shown for clarity. D) A weighted Fo – Fc map (contoured at 2.0) of the C-terminal region 
of PRMNS1. 
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Table 2. X-ray diffraction and refinement statistics  
for nSH3-PRMNS1 complex.  
 
 5UL6.PDB 
Data collection  
Space group P2 
Cell dimensions  
    a, b, c (Å) 27.65, 39.26, 29.03 
    , ,  ()  90.0, 98.43, 90.0 
Resolution (Å) 1.45 (1.48 to 1.45) 
Rmerge
b 8.9% (18.0%) 
I / I 9.0 (3.6) 
Completeness (%) 91.9 (62.5) 
Redundancy 3.5 (2.6) 
  
Refinement  
Resolution (Å) 1.45 
No. Reflections 10105 
Rwork/Rfree 0.165/0.187 
No. atoms 751 
    Protein 501 
    Ligand 114 
    Water 136 
B-factors  
    Protein 12.7 
    Ligand 18.2 
    Water 24.7  
r.m.s. deviations  
    Bond lengths (Å) 0.005 
    Bond angles () 0.799 
aThe numbers in parentheses refer to the highest  
resolution shell. 
bRmerge = ∑hkl ∑j |Ihkl,j - ⟨Ihkl⟩|/∑hkl ∑j⟨Ihkl⟩ 
 
 
 32 
 
 
Figure 14. The binding surface of the nSH3CRKII involved in the interaction with PRMNS1 is 
probed by NMR CSP analysis. (A) NMR HSQC spectra of the free nSH3 and nSH3-PRMNS1 
complex. The backbone resonances that shifted considerably upon binding of PRMNS1 are 
labeled. (B) NMR CSP of backbone amide resonances. The dotted line represents the chemical 
shift of mean + standard deviation.  (C) Mapping of binding interfacial residues on the crystal 
structure of the nSH3-PRMNS1. The binding interface probed by NMR CSP are shown in red.  
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The nSH3CRKII-PRMNS1 complex structure reveals a bipartite interface (Fig.13A). The N-
terminal region of PRMNS1 interacts with nSH3CRKII via hydrophobic interactions mediated by 
the PPLP motif. These hydrophobic interactions are commonly observed in other SH3-PRM 
complexes [142]. In contrast, the C-terminal region forms electrostatic interactions with a 
negatively charged surface of nSH3CRKII domain (Fig.13A). In this region, PRMNS1 forms two 
sets of short-range electrostatic interactions with the nSH3CRKII domain. One set is a salt-bridge 
network formed between the - amino group of K217 of PRMNS1 and three acidic residues 
(D147, E149, and D150) of the nSH3 domain (Fig.13B). Although this salt-bridge network has 
been observed in the complexes of nSH3CRKII and the PRMs of ABL[107] and C3G,[106] it is 
rarely observed in other SH3-PRM complexes (Table A1, Appendix I). The arrangement of these 
three acidic residues of the nSH3 domain is specifically optimized to accommodate the -amino 
group of K of a PRM. The replacement of this K with R was shown to reduce the binding affinity 
to the nSH3 domain by 10-fold [106, 107]. In contrast, most of SH3 domains that recognize 
PxxPx+ (+ represents either K or R) motifs prefer to bind to PRMs containing an R at this 
position [103]. Another important intermolecular contact is a bidentate hydrogen bond between 
E166 of the nSH3 and the backbone amides of Q218 and K219 of PRMNS1 (Fig.13C). To 
examine whether these intermolecular interactions are observed in other SH3-PRM complexes, 
we investigated all human SH3-PRM complex structures available in the PDB. Interestingly, 
none of the SH3 domains, except the nSH3CRKII, form both sets of intermolecular interactions 
with their cognate ligands (Fig.15 and Table A1, Appendix I). Therefore, these results explain 
why the 1918 NS1 is highly specific for the nSH3CRKII domain [59]. 
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Figure 15. Intermolecular hydrogen bonds in different SH3-PRM complex structures. (A) 
Specific salt-bridges between the acidic residues of the nSH3 domain and K-3 (i.e. K217) of 
PRMNS1. (B) Of the 58 human SH3-ligand complex structures, only one SH3 domain (Nebulin 
SH3, PDB ID: 4F14), except the nSH3CRKII, contains intermolecular salt-bridges between K of 
bound ligand and three acidic residues of SH3 domain (Table A1, Appendix I). However, the 
distances of these salt bridges are longer (2.7 – 3.5 Å) than those in the nSH3-PRMNS1 (2.7 Å for 
all three salt-bridges). (C) Interaction between E166 and PRMNS1. Of the 58 human SH3-ligand 
complex structures, two SH3 domains of CD2AP (panel d: 4WCI.pdb and panel e: 3U23.pdb) 
contain intermolecular hydrogen bonds between an acidic residue of SH3 domain (at position 
E166 in nSH3) and bound ligand. 
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The effect of net charges on the binding kinetics between nSH3CRKII and PRMs 
Despite the importance in binding selectivity, these short-range electrostatic interactions 
have also been observed in nSH3CRKII-PRMABL and nSH3CRKII-PRMC3G complexes, of which 
binding affinities are significantly lower than that of the nSH3CRKII-PRMNS1 complex [107]. 
Therefore, other factors likely make contribution to the binding energetics between nSH3CRKII and 
PRMNS1. While the binding surface of the nSH3 domain is negatively charged (Fig.13A), the 
PRMNS1 and PRMJNK1 contain net 5 and 0 positive charges, respectively. Therefore, long-range 
electrostatic interaction is likely to contribute to this large difference in Kd [143, 144]. To test this 
hypothesis, we examined the correlation between the net positive charges of PRMs and Kd. We 
indeed found that binding affinities correlate with the increasing net charge of PRMs (Fig.16A). 
Here, we included our previous results for binding of PRMABL to the nSH3CRKII domain [107]. 
It has been known that long-range electrostatics play an important role in accelerating 
association kinetics of protein-protein interactions [143, 145]. Therefore, we examined the effect 
of net charge of PRMs on binding kinetics to the nSH3CRKII domain. We measured kon and koff of 
the nSH3CRKII domain with PRMNS1 and PRMJNK1 using NMR 15N CPMG-RD experiment 
(Fig.16B and 16C) [135, 146]. A total of 11 and 6 backbone resonances of the nSH3 domain 
showed analyzable dispersion behavior upon binding of the PRMNS1 and PRMJNK1, respectively 
(Table 2, Appendix I and Fig.A1 and Fig.A2, Appendix II). These residues are located in the 
interface between the nSH3CRKII and the PRMs (Fig.A1 and Fig.A2, Appendix II). We observed 
flat dispersion profiles for the free nSH3 domain [107], indicating that the observed dispersion 
curve is the result of PRM binding to the nSH3 domain. 
Fig.16D shows that kon values correlate with the increasing net charge of PRMs. In this 
analysis, we included our previous results for binding kinetics between the nSH3CRKII and 
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PRMsABL [84]. The kon of the nSH3 and PRM
NS1 was measured to be 1.1 x 1010 M-1s-1, which is 
100-fold faster compared to that of nSH3CRKII and PRMJNK1 (Table 1). Furthermore, the kon of 
PRMJNK1, whose net charge is 0, is similar to the basal level kon (i.e. in the absence of electrostatic 
enhancement) between the nSH3CRKII and a PRM which is approximately 107 – 108 M-1s-1 [84]. 
Therefore, this large difference in kon is most likely due to long-range electrostatic acceleration 
[143, 145].  
Interestingly, the aforementioned short-range electrostatic interactions are conserved in all 
the nSH3CRKII-PRM complexes included in this analysis. Nevertheless, positively charged 
residues, except K217, in PRMNS1 do not form short-range interactions with negatively charged 
residues of the nSH3CRKII. Moreover, the side chain electron densities of the C-terminal positively 
charged residues (K219, R220 and K221) in PRMNS1 are noticeably weaker than other residues 
(Fig.13D), indicating conformational heterogeneity due to lack of specific interactions. Taken 
together, these results indicate that long-range electrostatics play an important role in binding 
thermodynamics and accelerating the association between CRKII and IAV NS1. These 
contributions of long-range electrostatics have been demonstrated in other protein-protein (or 
ligand) interactions.[144, 147, 148] 
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Figure 16. The effect of net charges on the binding kinetics between nSH3CRKII and PRMs. 
(A) The plot of net positive charge of PRMs and Kd values. The open circles represents the 
values for the nSH3CRKII and PRMsABL taken from Bhatt et al [12]. Representative NMR 15N 
CPMG-RD profiles (E149) measured for the binding of the nSH3 domain with (B) PRMNS1 and 
(C) PRMJNK. Date obtained at 14.1 Tesla and 18.8 Tesla are shown in black and red circles, 
respectively. The plot of net positive charge of PRMs and (C) kon values. The open circles 
represents the values for the nSH3CRKII and PRMsABL taken from Zeng et al.[16] 
 
Discussion  
Our results suggest that this rapid association provides 1918 NS1 with a temporal 
advantage to compete with host defense signaling processes. Rapid hijacking of CRKII by IAV 
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NS1 would interfere with CRKII-JNK1 and CRKII-ABL interactions before host antiviral 
immunity pathways are activated. Moreover, the koff of nSH3
CRKII-PRMNS1 is 35-fold and 15-fold 
slower than those of nSH3CRKII-PRMJNK and nSH3CRKII-PRMABL, respectively. It was indicated 
that IAV NS1 can translocate CRKII into the nucleus [96]. Therefore, the longer lifetime (i.e. 1/ 
koff) of the complex seems to help 1918 NS1 maintain contact with CRKII during the nuclear 
translocation process. These results suggest that the association and dissociation kinetics of 1918 
NS1 and CRKII are optimized for hijacking host protein-protein interactions. 
Despite its importance, very little is known about the molecular basis of the 1918 IAV 
pathogenicity. In this study, we have provided the structural, thermodynamic, and kinetic basis 
of the interaction between the PRM of 1918 NS1 and the nSH3 of CRKII. These results provide 
mechanistic insights into how IAV NS1 hijacks CRKII from its cellular binding partners, JNK1 
and ABL kinase. We anticipate that understanding the molecular mechanisms underlying viral 
hijacking of host protein-protein interactions will provide insights into the rational development 
of antiviral agents. 
 The SH3 domain is one of the most prevalent protein binding modules in the human 
proteome, and it plays important roles in diverse signaling processes [149]. Therefore, small-
molecule inhibitors targeting SH3 domains can be a powerful chemical biology tool for 
modulating protein-protein interactions [150]. However, the development of SH3 domain 
inhibitors has proven difficult because most of the SH3-ligand interactions has proven difficult 
because most of the SH3-ligand interactions are of low binding affinity and selectivity [151]. 
This low affinity is mainly due to the small and shallow binding interfaces, which are common 
features of undruggable targets. In light of this, understanding the molecular mechanism 
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undering exceptionally high affinity and selectivity of PRMNS1 to the nSH3 domain will provide 
insights into the design principles for potent SH3 domain inhibitors.  
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CHAPTER III 
THE MOLECULAR MECHANISM OF TIGHT BINDING BETWEEN PRM AND  
N-TERMINAL SH3 DOMAIN THROUGH FUZZY INTERACTIONS* 
 
Background 
There is growing interest in understanding molecular recognition mechanisms between 
PRMs and their cognate domains such as SH3 domains because PRM is one of the most common 
linear motifs in the eukaryotic proteome [109, 152].  PRMs are also highly enriched in 
intrinsically disordered proteins (IDPs) or intrinsically disordered regions (IDRs) [153]. 
Although they lack stable conformations, IDPs/IDRs mediate protein-protein interactions in 
signal transduction or transcription regulation [154-156]. Hence, it is of importance to 
understand the molecular mechanisms determining the binding affinity and selectivity of IDRs. 
Recent studies have shown that some IDPs/IDRs retain substantial conformational flexibility 
even in a complex with their binding partner. This mode of complex was described as a fuzzy 
complex [157]. Given the growing importance of fuzzy complexes in biological processes, 
elucidating their molecular recognition mechanism is essential.  
NS1 of IAVs plays an important role in suppressing the antiviral immune responses of 
host cells [158, 159]. Unlike common seasonal flu, the 1918 IAV uses NS1 to hijack host CRK 
proteins [59], and disrupts the CRKII mediated protein-protein [6, 51]. In Chapter III, we have 
shown that the viral hijacking occurs because a PRM in the NS1 binds to the nSH3 domain of 
                                                 
* Reproduced with permission from “Molecular Mechanisms of Tight Binding through Fuzzy Interactions” by 
Qingliang Shen, Jie Shi, Danyun Zeng, Baoyu Zhao, Pingwei Li, Wonmuk Hwang, Jae-Hyun Cho, 2018.  
Biophysical Journal. 114, 1313-1320. Copyright © 2018 Biophysical Society. 
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CRK with an exceptionally high affinity [6]. The binding affinity of the nSH3 domain with 
PRMNS1 is significantly higher than its interactions with other cellular binding partners. For 
example, the nSH3 domain binds PRMNS1 with ~3,000-fold higher affinity than the PRM of 
JNK1 [6, 107]. In Chapter III, it was suggested that the high affinity is due to long-range 
electrostatic interactions between positively charged residues in PRMNS1 and a negatively 
charged binding interface in the nSH3 domain (Fig.15A) [160]. However, the molecular 
mechanism by which long-range electrostatic interactions increase the affinity of PRMNS1 
remains elusive.  
Long-range electrostatic interactions play important roles in the molecular recognition in 
fuzzy complexes [80, 161]. Borg et al. proposed a polyelectrostatic model, in which multiple 
charges in an IDP increase its binding affinity to a rigid partner through non-specific, long-range 
electrostatic interactions as a binding mechanism of a fuzzy complex [148]. In this model, fuzzy 
complexes undergo fast conformational exchanges between multiple conformations, interacting 
with a folded partner through long-range electrostatic interactions.  
Here, we provide evidence that PRMNS1 retains conformational flexibility when 
complexed with the nSH3 domain, indicating a fuzzy complex. In addition, we present that the 
contribution of long-range electrostatic interactions and a detailed structural mechanism by 
which long-range electrostatics can increase the binding affinity of PRMNS1 to the nSH3 domain. 
We obtained these results using a combination of X-ray crystallography, NMR dynamics 
experiments, and molecular dynamics (MD) simulation. We find that structural disorder of the 
bound PRMNS1 plays a key role in mediating the long-range, nonspecific electrostatic 
interactions with the nSH3 domain. This work has been published in Biophysical Journal.  
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Experimental procedures 
Protein and peptides  
All protein samples for crystallization, fluorescence, and NMR experiments, were 
prepared as described in Chapter II. Synthetic peptides were purchased in a crude form, and 
further purified using reverse-phase high performance liquid chromatography in our laboratory. 
The N- and C-termini of peptides were acetylated and amidated, respectively. The peptide 
concentration was determined by measuring the UV absorption at 280 nm of a single tyrosine at 
the N-terminal end of the peptide. The isotope-labeled PRMNS1 contains an additional Gly 
residue at the C-terminus to prevent proteolysis during bacterial expression and purification. 
Based on our structure, we assume that one additional Gly at the C-terminus would not change 
structure and dynamics of PRMNS1 substantially. 
  
Crystallization and structure determination 
4 mM nSH3 was mixed with 5 mM PRMNS1 for the crystallization trials. The sample was 
crystallized by hanging drop vapour diffusion method in 0.1 M sodium acetate (pH 4.6), 30% PEG 
2000 and 0.2 M ammonium sulfate. A 1.45 Å resolution dataset was collected at 120 K using an 
R-AXIS IV++ image plate detector mounted on a Rigaku MicroMax 007HF X-ray generator. The 
data were processed using iMosflm in the CCP4 package[125]. The structure was determined using 
the nSH3 domain model (PDB ID: 5UL6) as search model using Phenix [126]. The PRMNS1 
peptide was modeled into the difference map manually in COOT[127] and refined with Phenix. 
The electrostatic potential surface of nSH3 domain was calculated using APBS and PDB2PQR 
[128-130]. 
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NMR spectroscopy  
All NMR experiments were conducted using protein samples in 20 mM sodium phosphate 
(pH 6.1), 80 mM NaCl, 0.02% sodium azide, 1 mM EDTA, 10 μM DSS (4,4-dimethyl-4-
silapentane-sulfonate), and 10% D2O at 25 C. NMR experiments were performed on Bruker 
Avance 600 MHz and 800 MHz spectrometers equipped with a cryogenic probe. NMR spectra 
were processed with NMRPipe[131] and analyzed with NMRViewJ (One Moon Scientific, Inc.) 
and CARA[132]. The temperatures of NMR sample were calibrated using the deuterated 
methanol-d4 [162].  
 
MD simulation  
Simulations were performed using CHARMM version 40a1 with param36 all-atom force 
field [163, 164]. An initial energy optimization was carried out for 1600 steps (with 400 steps 
using steepest descent algorithm and 1200 steps using the adopted basis Newton Raphson 
method) in the generalized Born with a simple switching (GBSW). The protein complex was 
solvated using the TIP3P water model and electrically neutralized with Cl- and Na+ ions. The 
system was then equilibrated for 160 ps under the NPT ensemble at 1 atm and 300 K. Production 
runs were performed under the NVT ensemble at 300 K.  
 
Cluster analysis 
After backbone heavy atoms in the nSH3 domain were superimposed, PRMNS1 
conformations from the MD trajectories were analyzed using a cluster analysis [165]. 
Agglomerative hierarchical clustering was used based on the similarity between different 
conformations, which is measured as squared Euclidean distance of the backbone heavy atoms in 
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PRMNS1. The average linkage was chosen to calculate inter-cluster similarity, which is the 
average of all pairwise similarities between observations in two clusters. The representative of 
each cluster was the conformation that has the smallest root-mean square deviation from the 
calculated average structure of the cluster. 
 
Binding assay 
The dissociation constants (Kd) of nSH3-PRM complexes were measured by monitoring 
the change of tryptophan fluorescence signal. Excitation wavelength was 295 nm. All binding 
assays were performed in a stirred 1-cm path length cuvette using a PTI QM-400 fluorimeter. 
Protein concentration used for the fluorescence-based binding assays was 0.1 μM. The 
measurements were done in 20 mM sodium phosphate (pH 6.1) and either 80 mM or 1 M NaCl 
at 25 C. The Kd was calculated by assuming a 1:1 complex, and by the global fitting of the 
repeatedly measured fluorescence intensities to the Eq.4. The reported Kd values are the average 
of 3 or 4 repeated measurements. 
 
Results 
Long-range electrostatic interaction increases the binding affinity of nSH3-PRMNS1 complex 
In Chapter II, we have suggested that positively charged residues, particularly in the C-
terminal region of PRMNS1 interact with a large negatively charged surface of the nSH3 domain 
through long-range electrostatic interactions [6]. To directly test the contribution of long-range 
electrostatics in increasing the binding affinity, we measured Kd values of the nSH3-PRM
NS1 
complex in the presence of 80 mM and 1 M NaCl. The Kd value decreased by more than 100-
fold in the presence of 1 M NaCl, compared to that in the presence of 80 mM NaCl (Fig.17).  
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We attributed this large decrease in the affinity to the screening of long-range 
electrostatics in the complex. The Debye screening lengths are 10.7 Å and 3.0 Å in the solution 
with ionic strength (I) = 80 mM and 1 M, respectively. Hence, long-range interactions are 
screened in a high ionic strength solution, while the short-range electrostatic interactions within 3 
Å remain effective under the same condition. Indeed, our previous crystal structure indicated that 
the distances of all short-range electrostatic interactions in the nSH3-PRMNS1 are within 3 Å 
(Fig.18). Moreover, all these short-range electrostatic interactions in the nSH3-PRMNS1 complex 
are well-conserved in the complexes with much weaker affinities [106, 107], indicating that 
these salt-bridges are not responsible for the unusually high affinity of PRMNS1.  
 
 
Figure 17. Fluorescence-based measurement of binding affinity between the nSH3 domain 
and PRMNS1 in the presence of 80 mM (triangles) and 1 M (circles) NaCl. The inset shows 
Kd values from repeated measurements. 
 
We further examined the effect of the positive charges in PRMNS1 on the binding affinity 
using mutagenesis. We replaced all the C-terminal positively charged residues (K219, R220, and 
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K221) with Gly. We chose Gly to minimize the effect of other types of amino acids on the 
intrinsic conformational propensity of PRMNS1 and to retain the flexibility of C-terminal region. 
As expected, the mutant PRMNS1 showed significantly lower affinity to the nSH3 domain. Its Kd 
is 0.9 μM, which is similar to that shown in the presence of 1M NaCl (Fig.19). Taken together, 
these data show that the long-range electrostatic interactions play an important role in increasing 
the stability of the nSH3-PRMNS1 complex.   
 
 
Figure 18. The short-range electrostatic interactions in the nSH3-PRMNS1. (A) The complex 
contains short-range electrostatic interactions between K217 of PRMNS1 and three acidic residues 
(D147, E149, and D150) in the nSH3 domain (PDB ID: 6ATV). The distances in the figure were 
measured between Nζ of K219 and Oδ/ε of the acidic residues. 
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Figure 19. Fluorescence-based measurement of binding affinity between the nSH3 domain 
and mutant PRMNS1. In this measurement, three C-terminal positively charged residues (K219-
R220-K221) are replaced by Gly. The Kd value is from two repeated measurements.  
 
New crystal structure displays alternative binding mode of bound PRMNS1  
In this study, we determined a new crystal structure of the nSH3-PRMNS1 complex, which 
displays a different binding mode of PRMNS1 from that in the previous structure (Fig.20, Fig.21, 
table 3). To distinguish the two conformations of PRMNS1, the previous and current structures are 
labeled as PRMNS1A and PRMNS1B, respectively. The two complex structures showed similar 
changes in overall solvent accessible surface area upon complexation: 923 Å2 and 1080 Å2 for 
nSH3-PRMNS1A and nSH3-PRMNS1B, respectively. The two bound PRMNS1 showed virtually 
identical structures with respect to the N-terminal and core PPLPPK motif, including all 
intermolecular short-range electrostatic interactions mediated by K217.  
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Table 3. X-ray diffraction and refinement statistics  
for nSH3-PRMNS1B complex.  
 
 6ATV.PDB 
Data collection  
Space group P6122 
Cell dimensions  
    a, b, c (Å) 39.84, 39.84, 171.95 
    , ,  ()  90.0, 90.0, 120.0 
Resolution (Å) 1.75 (1.78 to 1.75) 
Rmerge 10.2% (23.3%) 
I / I 16.8 (3.5) 
Completeness (%) 94.9 (67.0) 
Redundancy 12.0 (3.3) 
  
Refinement  
Resolution (Å) 1.75 
No. Reflections 8437 
Rwork/Rfree 0.184/0.205 
No. atoms 721 
    Protein 493 
    Ligand 114 
    Water 114 
B-factors  
    Protein 18.8 
    Ligand 18.8 
    Water 32.8  
r.m.s. deviations  
    Bond lengths (Å) 0.006 
    Bond angles () 0.781 
aThe numbers in parentheses refer to the highest  
resolution shell. 
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Figure 20. Comparison of crystal structures between the nSH3-PRMNS1A (green, PDB ID: 
5UL6) and nSH3-PRMNS1B (cyan, PDB ID: 6ATV) complexes. (A) Overlaid structure of the 
nSH3 domains. (B) Overlaid structures of PRMNS1A and PRMNS1B. 
 
 
Figure 21. A weighted Fo – Fc map (contoured at 2) of (A) PRMNS1B and (B) PRMNS1A. 
 
In contrast, the C-terminal regions of bound PRMNS1 showed a large conformational 
difference (Fig.20B). This is due to large changes in the backbone φ/ψ angles of Q218 from 
82.0 / 27.5 in PRMNS1A to 122.9 / 176.9 in PRMNS1B (Fig.20B). This results in drastic 
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changes in the intermolecular interactions mediated by positively charged residues in the C-
terminal end of Q218 in PRMNS1 (Fig.22). The most notable change is the exchange of positions 
between R220 and K219. In PRMNS1A, K219 is the major residue interacting with acidic residues 
in the RT-loop of the nSH3 domain. In PRMNS1B, R220 occupies the position and K219 is fully 
exposed to solvent (Fig.23A and 23B). Another noticeable change is that hydrogen bonds 
mediated by E166 in the nSH3 domain. E166 forms a hydrogen bond with backbone amide of 
Q218 in PRMNS1A, but it forms hydrogen bonds with backbone amide of Q218 and sidechain 
NH of R220 in PRMNS1B (Fig.23C and 23D). These results suggest that the bound PRMNS1 may 
undergo conformational exchange between the two alternative binding modes in solution state.  
 
 
Figure 22. Conformational difference in the C-terminal region of the bound (A) PRMNS1B 
and (B) PRMNS1A. Significant changes in backbone (C)  and (D) ψ angles of Q218 induced 
large changes in the conformations of positively charged residues in the C-terminal end of Q218. 
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Figure 23. Conformational difference in the C-terminal region of bound PRMNS1. Change in 
the positions of K219 and R220 in (A) PRMNS1A and (B) PRMNS1B. The hydrogen bonds 
between E166 of the nSH3 domain (gray) and (C) Q218 in PRMNS1A and (D) Q218 and R220 in 
PRMNS1B. 
 
Structural heterogeneity of PRMNS1 probed by NMR spectroscopy 
Using NMR spectroscopy, we examined whether the alternative binding of PRMNS1, 
detected by crystallography, is populated in solution-state. The NMR 1H-15N HSQC spectrum of 
15N-PRMNS1 bound to the 14N-nSH3 showed that the backbone HN resonance of Q218 shifted 
significantly downfield (10.47 ppm) because of the hydrogen bond with E166 of the nSH3 as 
shown in the crystal structures (Fig.23C and Fig.24A). However, the peak broadened 
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significantly at 25 C, indicating a chemical exchange between alternative conformations in 
intermediate NMR timescale. When we lowered the temperature of the NMR sample to 6 C, the 
backbone amide peak of Q218 was split into two (major and minor) peaks, indicating that the 
exchange between the two conformations is in the slow-exchange regime (Fig.24A). In contrast, 
other C-terminal residues showed one set of peaks at both 6 and 25⁰C (Fig.A3, Appendix II). 
 
 
Figure 24. 1H-15N HSQC spectra of bound PRMNS1. (A) Backbone amide resonances of Q218 
and (B) sidechain HNε resonances of R220 at 25 C (black) and 6 C (blue). 
 
To examine whether these split peaks correspond to the two crystallographic 
conformations of PRMNS1, we compared the calculated backbone 1H/15N chemical shifts of Q218 
in PRMNS1A and PRMNS1B with those of the major and minor peaks observed at 6 C. We used 
SHIFTX2 for the calculation of chemical shifts from the crystal structures [166]. The calculated 
1H/15N chemical shifts of Q218 were 9.64 ppm/122.63 ppm and 9.24 ppm/121.58 ppm for 
PRMNS1A and PRMNS1B, respectively. The differences in the calculated chemical shifts between 
PRMNS1A and PRMNS1B are comparable to those between the major and minor peaks, although 
the absolute chemical shifts differ between experimental and calculated values. This indicates 
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that PRMNS1A and PRMNS1B might correspond to minor (downfield-shifted) and major (upfield-
shifted) peaks, respectively (blue peaks in Fig.24A).  
We also observed that the side chain NH peak of R220 in the bound PRMNS1 was split 
into at least two peaks at 6 C (Fig.24B). Although we noticed another minor peak besides the 
two peaks, its intensity was too low for assignment. Hence, it was not considered in this study. 
The major peak (H = 7.53 ppm) shifted noticeably downfield than the minor peak (H = 7.34 
ppm). The SHIFTX2 calculation also yielded noticeably different chemical shifts for H-R220 in 
the two crystal structures: 7.26 ppm and 8.09 ppm for PRMNS1A and PRMNS1B, respectively. This 
is reasonable because the interaction between H-R220 and E166 of the nSH3 is present in 
PRMNS1B, but not in PRMNS1A. However, it should be noted that the chemical shift differences 
only allow indirect structural inference, and further structural characterization will be required 
for unambiguous conclusion.  
For further comparison, we analyzed the intramolecular NOESY spectrum between 
PRMNS1 and the nSH3 domain using 15N-labeled PRMNS1 bound to nonlabeled nSH3 domain 
(Fig.A4). However, the C-terminal residues only showed short-range intramolecular (i.e., within 
PRMNS1) crosspeaks, which are not characteristic enough for structural comparison with the 
crystal structures. This result indicates that the C-terminal positively charged residues in PRMNS1 
remain flexible when undergoing conformational exchange in the slow NMR timescale at 6⁰C.      
 
Dynamic disorder of PRMNS1 probed by NMR spectroscopy and MD simulation 
We characterized the conformational flexibility of bound PRMNS1 using NMR relaxation 
experiments. The {1H}-15N heteronuclear nuclear Overhauser effect (NOE) reports on backbone 
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dynamics in picosecond timescale [167]. Higher (> 0.7) NOE values correspond to ordered 
regions and lower (< 0.7) or negative NOE values indicate high conformational flexibility in 
picosecond to nanosecond timescale. Overall, NOE values for PRMNS1 were lower than those for 
the nSH3 domain (Fig.25A and Fig.A5, Appendix II). Interestingly, even the residues in the 
PRM-binding surface of the nSH3 domain showed higher NOE values than the bound PRMNS1. 
This feature has been observed in other fuzzy complexes [148, 168], in which a bound IDP/IDR 
retains high conformational flexibility on the surface of a rigid protein. Although the residues in 
the core PPLPPK sequence showed relatively high NOE values (~0.65), the N- and C-terminal 
residues were highly disordered (NOE < 0.4). These results indicate that the nSH3-PRMNS1 
complex is a partial fuzzy complex, in which the bound PRMNS1 is relatively rigid in the core 
region but highly flexible in the terminal regions.  
 
 
Figure 25. (A) {1H}-15N heteronuclear NOE and (B) 15N R2 of PRMNS1 in the complexed 
state. The asterisks represents the positions of Pro. The solid circles represents the positions of 
the residues whose peak intensities are too weak to measure. Black bars correspond to the C-
terminal residues showing different conformations in the two crystal structures.  
We also observed that the bound PRMNS1 is highly flexible in s – ms timescales. At 
25C, the 15N NMR R2 values of K217, Q218, and K219 of PRMNS1 were noticeably elevated, 
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compared to those of other residues. The elevated R2 value indicates the presence of 
conformational dynamics of bound PRMNS1 in s – ms timescales (Fig.25B) [169]. In particular, 
the linewidth of Q218 was severely broadened, such that accurate measurement of its R2 value 
was not possible. This is consistent with structural heterogeneity of this region observed in the 
crystal structures. Hence, the exchange between the two conformations, PRMNS1A and PRMNS1B, 
might be responsible for the elevated R2 values.  
The elevated R2 values are not due to the on-off process of PRM
NS1 to the nSH3 domain 
because R2 values of the PRM
NS1 binding sites in the nSH3 domain are not affected (Fig.A4, 
Appendix II). Our previous study has shown that the binding-unbinding processes of PRMNS1 
induces significant NMR line broadening in the nSH3 domain [6]. However, we cannot exclude 
the possibility in which unidentified conformations are involved in mediating the conformational 
exchange processes. These results indicate that conformation of PRMNS1 is highly dynamic over 
broad timescales ranging from picoseconds to milliseconds.   
To further elucidate the conformational dynamics of PRMNS1 in the bound state, we 
performed two all-atom 100 ns MD simulations, each using one of the crystal structures as the 
starting structure (Fig.26). The two simulations did not converge well with each other during the 
100 ns simulation time, indicating that the conversion between the two PMRNS1 conformations is 
slower than the simulation timescale. This is because the conversion requires large changes in 
φ/ψ angles of Q218 associated with breakage and re-formation of multiple interactions, such as 
E166nSH3-Q218PRMNS1 and E149nSH3-R220PRMNS1. Consistent with this, R220 formed a stable -
rayhydrogen bond with E149nSH3 with 89% occupancy in the simulation of PRMNS1B, whereas it 
did not form in the simulation of PRMNS1A.  The occupancy of E166nSH3-Q218PRMNS1 interaction 
was 17% and 64% in the simulation of PRMNS1A and PRMNS1B, respectively. These results are 
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consistent with our NMR data, indicating that N- and C-terminal regions undergo conformational 
exchanges in the microsecond to millisecond timescale. 
 
 
Figure 26. MD simulations of the nSH3-PRMNS1 complexes. (A) Representative PRMNS1 
structures were selected from cluster analysis (see Methods) of the MD trajectories using 
PRMNS1A (green) and PRMNS1B (cyan). The positively and negatively charged residues are 
shown in blue and red, respectively. Side chains were omitted in (B) for clarity.    
 
Effects of structural disorder of bound PRM on long-range electrostatic interactions with the 
nSH3 domain 
It was proposed that the polyelectrostatic model explains the thermodynamic contribution 
of long-range electrostatic interactions in a fuzzy complex [148]. Based on the model, Kd value 
decreases exponentially as the net charge of a disordered ligand increases. We have previously 
shown that the binding affinity between the nSH3 domain and PRMs depends exponentially on 
the net charge of the binding PRM [6]. However, the bound PRMNS1 is partially fuzzy, in which 
the terminal regions are highly flexible and its core PxxP sequence is relatively rigid. Thus, it 
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remains to be determined whether the partial fuzziness of the bound PRMNS1 increases 
multiplicity of long-range electrostatic interactions with the nSH3 domain, as assumed in the 
polyelectrostatic model. This is an important question because many fuzzy complexes might be 
partially fuzzy. 
However, it is difficult to test whether the structural disorder increases the number of 
long-range electrostatic interactions because there is no straightforward experimental method to 
tune conformational flexibility of the bound ligand. As an alternative approach, we compared the 
number of long-range electrostatic interactions between MD trajectories and crystal structures 
that represent mobile and static states of the bound PRMNS1 respectively. 
We first identified acidic residues in the nSH3 domain that are involved in electrostatic 
interactions with the positive charges in the bound PRMNS1 by measuring changes in the side 
chain carboxyl carbon chemical shifts (13C/O) of all acidic residues in the nSH3 domain 
between the free and complexed states. This analysis identified six acidic residues (D142, D147, 
E149, D150, D163, and E166) (Fig.27A). These residues are located in and around the PRMNS1-
binding interface in the nSH3 domain (Fig.27B). Next, we measured the mean pairwise distances 
between the acidic residues in the nSH3 domain and positively charged residues in PRMNS1 in 
our MD simulations and the two crystal structures (Table A3, Appendix I). In this analysis, K217 
in PRMNS1 was excluded because it is involved in well-defined short-range electrostatics, which 
are also present in other nSH3-PRM complexes. Interestingly, the mean pairwise distances 
calculated from the MD trajectories were considerably shorter than those calculated from the 
crystal structures (Table 4 and Table A3, Appendix I). One obvious exception in Table 4 was the 
distance between K221 in PRMNS1 and D163 in the nSH3 domain, which is shorter in the crystal 
structures because of the lattice contacts around K221. The distance would be longer without the 
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lattice contacts. These results indicate that partial disorder of the bound PRMNS1 increases the 
number of long-range electrostatic interactions, as assumed in the polyelectrostatic model. 
 
 
Figure 27. Detection of long-range electrostatic interactions between the nSH3 domain and 
PRMNS1 using NMR spectroscopy. (A) 13Cγδ chemical shift perturbations of all acidic residues 
in the nSH3 domain upon binding of PRMNS1. (B) Positions of acidic residues whose 13Cγδ 
chemical shifts are perturbed noticeably. Overlaid structures of PRMNS1A (green) and PRMNS1B 
(cyan) are shown. 
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Table 4. Differences in average pairwise distances between MD and crystal structures. 
aAverage distances of MD simulations of PRMNS1A and PRMNS1B. 
bAverage distances of two crystal structures (PRMNS1A and PRMNS1B). 
cThese distances were longer than 15 Å and were not included in the calculation. 
 
Although the polyelectrostatic model was developed to understand the binding 
mechanism of a fully fuzzy complex, its validity for partially fuzzy complex was not rigorously 
tested. Many IDP/IDR mediated complexes may be partially rather than fully disordered. 
Therefore, our results provide mechanistic insights into the role of non-specific, long-range 
electrostatic interactions in other partially fuzzy complexes as well.  
 
Discussion  
Many viral proteins interact with host modular binding domains, such as SH3 domains by 
mimicking the cellular linear binding motifs [170, 171]. Although cellular PRMs bind to their 
cognate SH3 domains with weak affinities (Kd ~ 10 M) [6, 107, 172], viral PRMs often show 
significantly higher affinities to the target SH3 domains [6, 147, 173]. Both viral and cellular 
PRMs contain conserved core PxxP motif, but peripheral sequences in viral PRMs contain more 
charged residues than the ones in the cellular PRMs [147, 173, 174]. Our study highlights that 
the pandemic IAV NS1 hijacks cellular CRK by exploiting the long-range electrostatic 
interactions mediated by disordered peripheral region of its PRM. Recently, it was indicated that 
Residues in 
PRMNS1 
Difference in Average Pairwise Distances (MDa–Crystalb) (Å) 
Acidic Residues in the nSH3 Domain 
D142 D147 E149 D150 D163 E166 
R211 negative 0.9 –c –c –c –c –c 
K219 –c negative 2.3 negative 1.3 negative 2.2 0.9 negative 0.5 
R220 –c negative 1.0 negative 0.4 negative 0.8 negative 1.1 negative 2.2 
K221 –c negative 3.4 negative 0.9 negative 1.5 3.8 negative 0.4 
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amphiphysin-2 SH3 domain and PRM in NS3 of the Chikungunya virus bind via 
polyelectrostatic interactions mediated by the positively charged disordered region in the PRM 
[147]. Interestingly, the binding affinity of this complex was also high (Kd = 24 nM). It is of 
interest that both viral proteins employ a similar strategy to hijack host signaling proteins 
containing SH3 domains. Therefore, it is likely that conformational dynamics within a complex 
state are closely related to functional roles of many SH3-PRM complexes [175]. We anticipate 
that elucidating the molecular mechanisms underlying binding affinity and selectivity of SH3-
PRM interactions will help understand host protein-protein interactions and design an inhibitor 
of viral infections.  
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CHAPTER IV 
MOLECULAR RECOGNITION OF HUMAN PHOSPHOINOSITIDE 3-KINASE BY 
NONSTRUCTURAL PROTEIN 1 OF PANDEMIC INFLUENZA VIRUS 
 
Background 
IAV is responsible for the majority of seasonal flu cases resulting in more than 30,000 
deaths every year in the United States alone [3]. Moreover, occasional emergence of pandemic 
IAV incapacitates vaccines and infects millions of people worldwide [176]. Four major flu 
pandemics occurred in the past 100 years, most recently in 2009. The deadliest one, which is 
often called “Spanish flu”, occurred in 1918 and resulted in more than 50 million deaths 
worldwide [4]. However, the molecular determinants of the high virulence of the 1918 IAV still 
remain unknown.  
NS1 of IAV has attracted considerable attention because of its role as a multifunctional 
virulence factor during viral infection cycle. The primary functions of IAV NS1 are to 
antagonize host innate immune responses, such as the expression of type I interferon, and to 
increase viral replication [42, 59]. NS1 consists of an RBD and ED, followed by an intrinsically 
disordered CTT (Fig.28A). The RBD primarily binds viral dsRNA and inhibits interferon-
induced oligonucleotide A synthetase [177]. ED and CTT play key roles in interfering with host 
antiviral immune processes by binding to a number of host proteins, including PI3K, CPSF30, 
CRK, TRIM25 of RIG-I, and PDZ proteins [49, 56, 58, 59, 178].  
One important function of NS1 during the infection cycle is to activate the PI3K 
signaling pathway [39, 59, 77, 78, 101]. Class IA PI3K is a heterodimeric enzyme composed of a 
regulatory p85 subunit and a catalytic p110 subunit (Fig.28A). The binding of NS1 ED to the 
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iSH2p85 subunit activates the p110 catalytic subunit. Although the underlying mechanism is not 
fully understood, NS1-mediated activation of the PI3K pathway results in increased IAV 
virulence by delaying cellular apoptosis[78] and/or by changing the spatial distribution of PI3K 
[54, 179].  
Although many free NS1 structures of diverse IAV strains have been determined, only a 
few complex structures of NS1 with host factors have been determined. Moreover, despite its 
importance in understanding the virulence of 1918 IAV [41, 180], there is no information 
concerning the structure of pandemic 1918 NS1 complexed with host proteins. Thus, the 
molecular recognition mechanism of 1918 NS1 remains poorly understood. Understanding the 
mechanism requires information on the structures of the free and p85-bound states of NS1 ED 
and on the structural transition between the two states. Elucidating the molecular recognition 
mechanism by which 1918 NS1 binds iSH2p85 can provide the opportunity for the rational 
design of antiviral therapeutics that could prevent or treat future pandemics [53]. 
To gain mechanistic insights into the molecular recognition of 1918 NS1 for human 
iSH2p85, we determined the structures of 1918 NS1 ED in the free and iSH2p85-bound states 
using NMR spectroscopy and X-ray crystallography, respectively. Our study revealed that the 
1918 NS1 ED requires a conformational switch prior to binding to iSH2p85. Using NMR 
relaxation dispersion experiments, we further revealed that the free 1918 NS1 ED undergoes a 
dynamic conformational switch in the sub-millisecond (sub-ms) timescale between iSH2p85-
binding-incompetent and -competent states. Moreover, structural comparison of NS1 proteins 
from different IAV strains indicated that the intrinsic dynamics might be a common molecular 
recognition mechanism harnessed by other IAV NS1 proteins. These findings collectively 
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highlight the functional importance of the conformational dynamics (dynamic motion) in the 
molecular recognition mechanism of 1918 NS1 ED. 
 
Experimental procedure 
Protein sample preparation 
Genes encoding 1918 NS1 and iSH2p85 proteins were prepared by gene-synthesis service 
from Genscript. Full-length NS1-W187R, , NS1 ED-W187R,  NS1 ED-CTT-W187R ad NS1 
ED-WT were expressed in BL21 (DE3) E.coli cells with a His6 and SUMO tags, and purified by 
Ni2+ NTA column and gel-filtration chromatography. iSH2p85 domain was expressed in E.coli 
and purified in the same as NS1 proteins. Purity of protein samples was confirmed using SDS-
PAGE; all samples were >95% pure. For stable isotope labeling, 2 L bacterial cultures were 
grown in LB media to an OD600 of ~0.6 and then, bacteria were spun-down to transfer to 1 L of 
M9 minimal media supplemented with 1 g/L of 15N NH4Cl and 2g/L 
13C D-glucose. Protein 
expression was then induced with 0.5 mM IPTC for 4 h at 37 C. His6- and SUMO-tag were 
cleaved using SUMO protease after Ni2+ NTA column purification. Cleaved protein was further 
purified by second Ni2+ NTA column and gel-filtration chromatography.  
 
BLI experiments 
The binding of iSH2p85 to immobilized NS1 constructs was measured at 25 C using an 
Octet RED biolayer interferometer (Pall ForteBio). Avi (streptavidin) or His6 tagged NS1 
proteins were immobilized on Ni-NTA or high precision streptavidin biosensors using a ~4ug/ml 
protein concentration. The Kd obtained was not affected by reversing the analyte and ligand in 
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which His6-tagged iSH2
p85 is immobilized and free NS1 ED is in wells (Fig.A6, Appendix II). 
The buffer was 20 mM sodium phosphate (pH 7.0), 80 mM NaCl, 1% BSA, and 0.4 M trehalose. 
The full-length NS1 for BLI experiments contained His6 tag followed by SUMO to promote 
solubility and keep it in monomer form. NS1 ED proteins contained either N-terminal His6 or 
Avi tag without SUMO. The Kd values were determined using kinetic rate constants (Kd = koff / 
kon) calculated by applying a single exponential function with the assumption of a 1:1 binding 
stoichiometry. Association and dissociation phases were measured for 110 s and 60 s, 
respectively. All measurements were performed at least three times. Experimental kobs values 
were measured by fitting a single exponential equation to the association phse (0 – 120 s) of BLI 
data. 
 
NMR sample preparation  
NMR samples of 1918 NS1 ED were prepared in an NMR buffer consisting of 20 mM 
sodium phosphate (pH 7.0), 80mM NaCl, 1mM EDTA, 10% D2O, 10 M DSS (4,4-dimethyl-4-
silapentane-sulfonate). For resonance assignment and structural determination 13C, 15N-labled 
NS1 ED was concentrated to 200 uM in NMR buffer. For CPMG-RD experiments, 15N-labled 
protein was prepared with 0.4 M trehalose in NMR buffer. For R1 and R2 relaxation 
measurements, (13C, 15N)-labeled protein was prepared in NMR buffer without trehalose.   
 
NMR resonance assignment and structure determination of 1918 NS1 ED 
NMR data were collected at 298 K on Bruker Avance III 600 MHz and 800 MHz 
spectrometers equipped with a cryogenic probe at Biomolecular NMR center (Texas A&M 
University). Resonance assignment was carried out using a set of standard triple resonance 
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experiments as described elsewhere. The data were processed using NMRPipe [131] and 
resonance assignment was conducted using Sparky [181]. 
Backbone and sidechain resonance assignments were performed using a standard 
backbone-directed triple resonance experiments in combination with NOE spectroscopy 
(NOESY). The resonance assignments have been deposited in the Biological Magnetic 
Resonance Bank (BMRB) with accession code 12032. The structure of free 1918 NS1 ED was 
calculated using simulated annealing methods based on NOESY-derived distance restraints and 
torsion angle restraints calculated by TALOS+ [182]. Distance restraints were derived from NOE 
cross peaks in 13C-NOESY-HSQC and 15N-NOESY-HSQC spectra with mixing times of 80 and 
100 ms. The automated NOESY peak assignment was performed via the CYANA Noeassign 
macro [183]. Cross-peak intensities were converted into distances using CYANA [184]. 100 
structures were analyzed and the 40 structure with the lowest residual CYANA target function 
values were subjected to further energy minimization with R2/R1 ratio and explicit water 
refinement protocol of Xplor-NIH [185]. The resulting 20 lowest structures were further refined 
using YASARA webserver [186] and were deposited in the PDB with ID 6NU0. The full 
structural statistic for the ensemble of 20 lowest energy structures are shown in Table 6. 
 
NMR 15N relaxation measurements 
Measurements for R1 and R2 rate constants were performed as described elsewhere. 
Briefly, for R1, five relaxation time points were taken between 100 ms and 1s. For R2, five 
relaxation time points were taken between 4 and 120 ms, For R1 and R2 measurements, a recycle 
delay of 2 s was used between transitions.  
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CPMG-RD experiments [135, 146] were recorded at two static magnetic fields (600 and 
800 MHz) with CPMG frequencies (vcpmg), ranging from 50 to 1000 Hz, as pseudo-3D 
experiments with a constant-time CPMG evolution period of 30 ms. Analysis of R2,eff(νCPMG) 
profile was performed as described elsewhere. The uncertainty of R2,eff was estimated by 
comparing the peak intensities of duplicated experiments. The CPMG-RD profile was fitted 
using the Carver-Richards equation (Eq.2) [136, 140].   
 
Chemical shifts (CS) prediction using SHIFTX2 
Prediction of CS from structural models was performed using the SHIFTX2 [166]. The 
CS for the iSH2p85-bound-like state was predicted using the NS1 structure in the complex 
(PDB:3L4Q) after removing iSH2p85. The CS for free state was estimated by taking the average 
of NMR-derived and SHIFTX2-derived CS using NMR (PDB:6NU0) and crystal (PDB:3L4Q) 
structures for free 1918 NS1 ED [61]. This averaging is needed to take into account the 
uncertainty of predicted CS values using SHIFTX2.  
 
Crystallography  
The 1918 NS1 ED-iSH2p85 complex was crystallized at 277 K by hanging drop vapor 
diffusion in 20 mM sodium phosphate (pH 7.0) and 80 mM NaCl. A 100 μM of NS1 ED was 
mixed with a 100 µM iSH2p85 to prepare the complex. The protein mixture precipitated 
immediately after the mixing. The precipitated mixture was used for crystallization trials. A 1.45 
Å resolution dataset was collected at 120 K using an R-AXIS IV++ image plate detector mounted 
on a Rigaku MicroMax 007HF X-ray generator. The data were processed using iMosflm in the 
CCP4 package [125]. The structure was determined using previously reported structure (PDB ID: 
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3L4Q) of mouse-adapted Puerto Rico/8/34 (PR8) NS1 ED complexed with bovine iSH2p85 as a 
search model using Phenix [126]. 
 
SAXS 
Solution scattering data was collected at the Life Sciences X-ray Scattering beamline 
(LiX) at NSLSII, Brookhaven National Laboratory, Upton, NY. LiX utilizes an undulator source 
and a Si(111) monochromator. Kirkpatrick-Baez (KB) mirrors focus the beam on a secondary 
source and X-ray energy was 12 keV with a beamsize of ~400um. An in-house solution 
scattering box houses a movable 3 channel flow cell, such that proteins in solution flow through 
the beam during collection. Data is collected on 3 Pilatus detectors (SAXS: Pilatus 1M, 2 offset 
WAXS detectors: Pilatus 300K). The data was merged, averaged, subtracted and packed into 
HDF5 format using our in-house py4xs software (Github), with data visualization in jupyter 
notebook. Inline size exclusion chromatography coupled with small-angle X-ray scattering 
(SEC-SAXS) data was collected at room temperature using a Shimadzu HPLC system in 
isocratic mode. After injection into the chromatography system and elution from the column, 
fluid is split 1:3 between UV/RID detectors and the X-ray flow cell. Injection of 150 µl of 100 
µM NS1 was performed using the Shimadzu Sil10-A autosampler. Isocratic separation was done 
using a Superdex Increase 200 10/300 GL column (GE healthcare) at a flowrate of 0.45 mL/min. 
1648 X-ray image frames with 1 second exposure were collected. ScÅtter was used for Guinier 
analysis and estimation of Rg [187]. The ab initio model was generated using DAMMIF [188]. 
The SAXS profile and Rg for NS1 ED structure was calculated using MultiFoXS [189]. 
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Results 
1918 NS1 ED, but not RBD, is responsible for binding to iSH2p85 of PI3K 
Isolated NS1 ED tends to form a homodimer, which contributes to the binding of full-
length NS1 to dsRNA[54]. However, interaction of NS1 ED with some host proteins, including 
p85, is known to be mediated by its monomeric form[190]. To investigate the molecular basis 
of the p85-recognition mechanism by the 1918 NS1 ED monomer, we incorporated an W187R 
substitution, which was shown to prevent NS1 ED homodimerization and precipitation [45]. 
Arginine is the only amino acid that can be replaced with W187 without altering the overlapping 
NS2 open reading frame [54]. However, it was shown that NS1-W187R has slightly lower 
dsRNA binding affinity relative to wild-type NS1 [45, 191]. To confirm that W187R substitution 
does not affect the binding to iSH2p85, we compared the in vitro binding affinities (Kd) of 1918 
NS1 ED wild type (ED-WT) and NS1 ED-W187R using biolayer interferometry (BLI) (Fig.28). 
The two proteins have virtually identical affinities, showing that W187R substitution does not 
affect the binding to iSH2p85. This result is consistent with the previous finding that NS1 ED 
dimerization through W187 is not required for the interaction with iSH2p85 [61]. However, it 
remains unknown whether the RBD and CTT contributes to the binding of NS1 ED to p85. 
Thus, we measured the affinity of full-length 1918 NS1-W187R (residues 1 – 230) and NS1 ED-
CTT-W187R (residues 80-230) to iSH2p85. The affinity (Kd = 27 nM and 45 nM) was highly 
similar to that of 1918 NS1 ED-W187R (Fig.28B and Table 5), indicating that RBD and CTT are 
not involved in binding iSH2p85. These results justified the use of 1918 NS1 ED-W187R to 
study the interaction with iSH2p85.  
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Figure 28. The binding affinity and kinetics of different constructs of 1918 NS1 and 
iSH2p85β measured by BLI. (A) A schematic diagram showing the domain organization of p85β 
subunit of PI3K and 1918 NS1. 1918 NS1 ED-W187R (B), NS1 ED-CTT-W187R (C), wild type 
1918 NS1 ED (D) and full-length 1918 NS1-W187R (E) were immobilized on biosensors, while 
a range of concentration (10, 25, 50, 75, 100 nM) of iSH2p85β were used as analytes kept in 
solution. 
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Table 5. Thermodynamic and kinetic parameters for the binding between  
different constructs of 1918 NS1 and iSH2p85β measured by BLI.  
 
Ligands Kd (nM ) kon( 104 M-1s-1 ) koff( 10-3 s-1 ) 
ED-W187R (80-205) 35.5 ± 0.4 3.94 ± 0.04 1.40 ± 0.01 
ED-CTT-W187R(80-230) 44.7 ± 1.1 8.94 ± 0.21 4.07 ± 0.04 
ED-WT (86-230) 29.1 ± 0.7 7.06 ± 0.08 2.05 ± 0.04 
NS1-W187R (1-230) 27.4 ± 0.6 7.93 ± 0.14 2.17 ± 0.03 
 
1918 NS1 ED-W187R is a monomer in solution 
The structure of the free 1918 NS1 ED-W187R (hereinafter 1918 NS1 ED unless 
otherwise noted) was determined using solution NMR spectroscopy as described in the 
experimental procedures. The full structural statistic for the ensemble of the 20 lowest energy 
structures are shown in Table 6. Overall, the solution NMR structure is similar to the recently 
reported crystal structure of 1918 NS1 ED-W187A (Fig.29A and Fig.A7, Appendix II). The 
most noticeable difference is that the NMR structure is a monomer, while the crystal structure 
contains two NS1 ED molecules in an asymmetric unit. Because NS1 ED dimerization can affect 
binding to iSH2p85, we sought to determine whether 1918 NS1 ED exists in the solution as a 
monomer or dimer. We measured the correlation time (c) for the rotational diffusion process of 
1918 NS1 ED using NMR 15N R2/R1 ratio. The measured c (= 6.8 ns) agrees well with the value 
(c = 6.72 ns) calculated using a monomeric NMR structure.  
For further confirmation, we performed small-angle X-ray scattering (SAXS) analysis on 
1918 NS1 ED (Fig.29B). The experimental SAXS profile matches well with the one calculated 
using NMR structure, with experimental and calculated Rg values of 15 Å and 14 Å, 
respectively. The NMR structure of 1918 NS1 monomer was also fitted well into the SAXS 
envelope structure calculated by ab initio model using DAMMIN (Fig.29C). The protein 
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concentration for the SAXS measurement was approximately 100 μM. These results along with 
the NMR study indicated that the 1918 NS1 ED-W187R forms a monomer in solution as long as 
protein concentration is <100 μM. 
 
Table 6. The structural statistics for the ensemble of 20 lowest  
energy NMR structures of 1918 NS1 ED. 
 
NMR distance and dihedral constraints 
 
   Total NOE (intramolecular) 1562 
   Intra-residue 386 
   Inter-residue 
 
      Sequential (|i-j| = 1) 498 
      Non-sequential (|i-j| > 1) 678 
Total dihedral angle restraints 
 
   Phi 109 
   Psi 109 
  
 
Structure statistics 
 
Violations (mean and s.d.) 
 
   Distance constraints (>0.1 Å) 0.19 ± 0.00 
   Dihedral angle constraints (>5 ) 4.62 ± 0.19 
   Max. dihedral angle violation (°) 21.31 ± 2.42 
   Max. distance constraint violation ( Å) 1.84 ± 0.07 
Average RMSD to mean (Å) 
 
   Heavy atom 1.08 ± 0.11 
   Backbone 0.56 ± 0.11 
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Figure 29. 1918 NS1 ED-W187R exists as a monomer in solution. (A) The lowest energy 
NMR structure of 1918 NS1 ED-W187R. (B) SAXS scatter data (black) for 1918 NS1 ED-
W187R was overlaid with the scattering profile calculated from the lowest energy NMR 
structure (red). (C) Ab-initio model of 1918 NS1 ED-W187R calculated by 
DAMMIN/DAMMIF from SAXS data superimposed with the NMR structure of 1918 NS1 ED-
W187R.  
 
Conformational heterogeneity and dynamics of free 1918 NS1 ED  
The solution structure of 1918 NS1 ED showed conformational heterogeneity in three 
regions comprising a part of antiparallel -sheet (region-1; 1-4-5 strands), helix α1 (region-
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2), a Pro-rich loop (region-3; residues 162 - 172), and the C-terminal helix (region-4) (Fig.30A). 
The backbone (C) RMSD of these regions was significantly larger than other regions among 
the ensemble structures (Fig.30B). Furthermore, five resonance peaks (139 – 140 and 142 – 144) 
in region-1 were missing in the 1H-15N HSQC spectrum because of severe line broadening, 
indicating the dynamic motion of the region in the intermediate NMR timescale. We further 
confirmed that the structural heterogeneity is mainly due to the internal dynamics of 1918 NS1 
ED. For this, the product of NMR R1 and R2 rate constants were compared (Fig.30C). The effects 
of conformational exchange in the μs-ms timescale significantly raise the R1R2 values. The 
locations of the residues whose R1R2 values are elevated overlapped with conformationally 
heterogeneous regions in the NMR ensemble (Fig.30D). This indicates that the conformational 
heterogeneity is due to sub-ms dynamic motion of free NS1 ED. 
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Figure 30. The conformational exchange of free 1918 NS1 ED probed by NMR. (A) The 
regions that shows conformational heterogeneity in the ensemble of 20 lowest energy NMR 
structures of free NS1 ED are highlighted in the left figure. The figure on the right shows the 
lowest energy NMR structure of free NS1 ED.  The antiparallel -sheet (region-1), helix α1 
(region-2), the Pro-rich loop (region-3), the C-terminal helix (region-4) are shown in green, cyan, 
orange, magenta, respectively. (B) Plot of the average backbone (C) RMSD per residue of the 
20 free NS1 ED NMR structures. (C) The NMR R1R2 values for free 1918 NS1 ED. (D) The 
residues whose R1R2 values are elevated are mapped on the lowest energy NMR structure of free 
1918 NS1 ED. 
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Structure of the 1918 NS1 ED-iSH2p85β complex  
We determined the crystal structure of the 1918 NS1 ED-iSH2p85β complex to 2.75 Å 
resolution (Fig.31A and Table 7). This is the first structure of 1918 NS1 ED complexed with a 
human protein. While the asymmetric unit contains two 1918 NS1-iSH2p85β complex molecules, 
the functional complex in the physiological condition is a 1:1 complex [61]. Using BLI, we also 
found that the binding of 1918 NS1 ED and iSH2p85β could be well-modelled using 1:1 binding 
stoichiometry (Fig.28B). Furthermore, we tested whether the binding monitored by BLI was the 
same as depicted in the crystal structure, in which the highly conserved Y89 of 1918 NS1 ED 
forms a hydrogen bond to D569 of iSH2p85β (Fig.31B). The Y89F mutation abolished the binding 
to iSH2p85β (Fig.31C), indicating that BLI-derived affinity corresponds to the binding mode 
shown in the crystal structure. The structure showed a predominantly hydrophobic binding 
interface, with hydrophobic and hydrophilic occluded surface areas in the complex of 764.4 Å2 
and 467.2 Å2, respectively (see Table A4, Appendix I and Fig.A8, Appendix II for all interface 
residues). These features are similar to those for the complex between PR8 (Puerto Rico 8/ 34/ 
H1N1) NS1 ED and bovine iSH2p85β. 
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Figure 31. The conformation change of 1918 NS1 ED upon iSH2p85β binding. (A) The 
structure of 1918 NS1 ED in complex with iSH2p85β. 1918 NS1 ED and iSH2p85β are shown as 
blue cartoon and orange surface models, respectively. The same colors are used for the regions 
of 1918 NS1 ED that shows conformational exchange as described in Fig.30A. (B) The hydrogen 
bond formed by Y89 of 1918 NS1 ED and D569 of iSH2p85β. (C) BLI sensorgram showing the 
binding of Y89F mutation of 1918 NS1 ED to iSH2p85β. (D) The overlaid structures of 1918 NS1 
ED in the free and iSH2p85β-bound states. (E) The plot of RMSD per residue between the free 
and complexed states was shown as black line, while the RMSD per residue of free NS1 ED 
NMR structures was shown in red. (F) The plot of RMSD per residue between the free and 
complexed states was shown as black line, while R1R2 values for free 1918 NS1 ED
 was shown 
as closed circle. 
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Table 7. X-ray diffraction and refinement statistics                                 
for 1918 NS1 ED-iSH2p85β complex.  
 
 NS1-iSH2p85β complex 
Data collection  
Space group P1 21 1 
Cell dimensions  
    a, b, c (Å) 60.98, 94.03, 67.22 
    , ,  ()  90.00, 105.31, 90.00 
Resolution (Å) 2.75 
Rmerge 13.8% (54.3%) 
I / I 6.7 (2.1) 
Completeness (%) 100 
Redundancy 3.7 (3.7) 
  
Refinement  
Resolution (Å) 2.60 
No. Reflections 22581 
Rwork/Rfree 0.2269/0.2545 
No. atoms 4320 
    Protein 4231 
    Water 89 
B-factors  
    Overall 57.5080 
aThe numbers in parentheses refer to the highest  
resolution shell. 
 
 
Comparison of 1918 NS1 ED structures in the free and iSH2p85β-bound states revealed 
that a substantial conformational change is needed in 1918 NS1 ED upon binding to iSH2p85β. 
Especially, the β1-β4-β5 strands in region-1 undergo a large conformational shift to avoid steric 
clash with iSH2p85β (Fig.31D). Intriguingly, the NS1 ED regions with a large RMSD between the 
free and complexed states agree well with conformationally heterogeneous regions in the NMR 
ensemble structures (Fig.31E) and dynamic regions (Fig.31F). These results indicate that the 
conformational dynamics in free 1918 NS1 ED is functionally important for the binding to 
iSH2p85β.  
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Rearrangement of the 1918 NS1 ED hydrophobic core during the conformational transition 
We found that conformational change of 1918 NS1 ED upon binding iSH2 p85β is 
accompanied by rearrangement of the hydrophobic packing. In the free state, a hydrophobic 
cluster (F134, V136, L141, and F201) holds the C-terminal -helix next to region-1 (Fig.32A). 
In the bound state, the side chain of F201 in the C-terminal helix rotates out and the space is 
filled by the translational shift of other hydrophobic side chains, resulting in the overall shift of 
region-1 (Fig.32B). Repacking the hydrophobic cluster leads to the change in the rotameric 
position of Y89 side chain so that it fits onto the surface of iSH2p85 and forms a hydrogen bond 
with D569 in iSH2p85, which is critical for the binding (Fig.32C). The position of Y89 in the 
free state sterically clashes with the surface of iSH2p85. The hydrophobic rearrangement in 1918 
NS1 ED increases the exposed hydrophobic surface area by approximately 100 Å2 in the bound 
state compared with the free state. Intriguingly, the residues in the hydrophobic cluster are highly 
conserved across IAV strains, indicating that the conformational change might be a common 
feature in NS1 proteins (Fig.32D). This is further elaborated in the Discussion.  
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Figure 32. The rearrangement of the 1918 NS1 ED hydrophobic core upon iSH2p85β 
binding. (A) The packing of hydrophobic cluster of free 1918 NS1 ED. The hydrophobic 
residues are represented as cyan sticks. (B) The repacking of hydrophobic core in iSH2p85β bound 
1918 NS1 ED. (C) The hydrophobic residues of free and bound state 1918 NS1 ED are overlaid. 
(D) A sequence logo diagram representing the conservation of hydrophobic cluster for NS1 ED 
of IAVs.    
 
Characterization of the dynamics in 1918 NS1 ED 
According to our structural study, the simplest binding mechanism of 1918 NS1 ED and 
iSH2 p85β is a two-step binding model, consisting of conformational exchange and binding steps 
(Fig.33A). Moreover, the structure of iSH2 p85β does not change upon the binding of NS1 ED 
[192] (Fig.A9, Appendix II), suggesting that the proposed two-step binding scheme from the 
perspective of NS1 ED is reasonable.  
For experimental validation of the proposed model, we first characterized the sub-ms 
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timescale dynamics in 1918 NS1 ED using NMR 15N R2 CPMG-RD experiments, which allows 
the estimation of residue-specific conformational exchange rate constant kex (= kf + kr), and the 
population and 15N chemical shift difference (∆) between the two exchanging conformational 
states [134, 135]. A total of 23 15N resonances exhibited exchange contribution (R2,eff) in the 
experiment. All of the residues are located in the regions that undergo conformational change 
upon binding to iSH2p85 (Fig.33B). Among the residues, 13 are well isolated and exhibited an 
R2,eff larger than 2.5 s
-1, which is adequate for quantitative data fitting. The NMR CPMG-RD 
data were fit to a two-state exchange model using the Carver and Richards equation [136, 137] 
(Fig.33C).  
Global fitting including all the residues yielded that kex (= kf + kr) is 2164  690 s-1. The 
population of p85-binding-competent state (i.e., minor state) was estimated to be 2–10 % of the 
entire population: the 2 of the global fitting was the lowest with a small margin when the 
population was 2% within the range (Fig.33D). Based on these results, we estimated that the kf 
and kr range from 40 to 220 s
-1 and 2124 to 1944 s-1, respectively. This result is consistent with 
our structural analysis, in which the free 1918 NS1 exhibited mainly the iSH2p85-binding-
incompetent state. This result also shows that the conformational transition occurs cooperatively, 
otherwise the global fitting would not work because the kex values would vary significantly for 
different residues. 
Next, we sought to elucidate whether the dynamic motion of free 1918 NS1 ED 
corresponds to the conformational switch between iSH2p85-binding-incompetent (major state) 
and binding-competent (minor) states. If so, the chemical shift difference (∆ = incompetent – 
competent) obtained by fitting to the CPMG-RD profile should match with the measured chemical 
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shift difference ∆ (= free – bound) between the two states. However, the direct measurement of 
bound was not possible because of the extremely low solubility of the 1918 NS1 ED-iSH2p85b 
complex. Alternatively, we used SHIFTX2 to calculate the chemical shift difference between the 
free and iSH2p85b-bound NS1 ED structures. Thus, the ∆SHIFTX2 represents the estimated 
chemical shift change of 1918 NS1 ED between the p85b-binding-incompetent and -competent 
conformations. We found that the ∆SHIFTX2 correlates reasonably well with the fitted ∆CPMG, 
indicating that the free 1918 NS1 ED does undergo a dynamic conformational switch with the 
iSH2p85-bound-like state (Fig.33E). As noted above, 1918 NS1 ED exposes a larger solvent-
accessible hydrophobic surface area in the bound state than in the binding-incompetent state. 
This might be the reason that the binding-competent conformation is the thermodynamically 
minor state. Taken together, these results establish that the transiently populated (relaxation time 
of ~500 s) minor (2-10%) state of 1918 NS1 ED resembles the conformation in the iSH2p85-
bound form. Given that the minor state is essential for binding iSH2p85, these characteristics are 
reminiscent of the conformational selection model for the target recognition mechanism. 
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Figure 33. The dynamics in free 1918 NS1 ED. (A) A schematic diagram showing the two-step 
binding model of 1918 NS1 and iSH2p85β. (B) The residues whose 15N resonances exhibit 
measurable exchange contribution (R2,eff) in the CPMG-RD experiment are shown as spheres. 
The residues whose R2,eff are larger than 2.5 s
-1 are shown as red spheres,. (C) Representative 
(T91) NMR 15N CPMG-RD profiles measured for the free 1918 NS1 at 14.1 (black) and 18.8 T 
(red). (D) The 2 values of the global fitting with different populations of the minor species. (E) 
Plot of ∆SHIFTX2 and ∆CPMG.  
  
Discussion 
Studies on how protein dynamics contributes to the molecular recognition of a viral 
protein for its host targets provides fundamental knowledge in protein-protein interactions and 
also allows rational design of antiviral therapeutics. The mechanistic role of conformational 
dynamics in molecular recognition process differs in two limiting cases: conformational 
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selection (CS) and induced fit (IF) mechanism [193]. In the CS model, conformational excitation 
to a binding-competent state is a prerequisite to specific binding. In the IF model, conformational 
relaxation from higher-energy-bound-state to lower-energy-bound-state results in a specific 
binding. Although our study supports the binding of 1918 NS1 ED and iSH2p85 through the CS 
mechanism, binding of the open state to iSH2p85 was not directly observed. This is mainly due 
to that the open state is marginally populated (2 – 10 %) with a short lifetime (< 500 μs). Thus, it 
remains to be determined whether the open state leads to the binding to iSH2p85 as suggested in 
CS mechanism (Fig.33A).  
Recent studies showed that an unequivocal distinction between CS and IF mechanisms is 
possible through rapid-kinetics experiments at a wide range of protein concentrations, especially 
including stoichiometric binding conditions where both protein concentrations are similar. 
However, a fluorescence-based stopped-flow experiment was not applicable because 1918 NS1 
ED-iSH2p85 binding does not change any intrinsic fluorescence signal (Fig.A10, Appendix II).  
As an alternative approach, we analyzed the pseudo-first-order kinetic data (i.e., [NS1] 
<< [iSH2p85]) from BLI. The binding rate constant kobs in CS mechanism under the pseudo-first-
order approximation is expressed as 
 
 
2
[ ] [ ] 4 [ ] / 2obs f r on off on off f r r onk k k k L k k L k k k k k L
          
 
       Equation 6 
 
Therefore, when the dynamic conformational switch occurs in a much faster timescale 
than the following binding process in CS mechanism, the y-intercept of the linear fit to the kobs 
vs [iSH2p85] is expected to yield koff. Indeed, the linear fitting to the plot of measured kobs vs 
 84 
 
[iSH2p85] provided a y-intercept (0.0026 s-1) close to measured koff (0.0021 s
-1) as expected 
(Fig.34A).  
Understanding how NS1 sequence variation in diverse IAV strains affects the PI3K 
activation is important to predict the virulence of newly emerging IAVs [85, 108, 119]. Here we 
discuss how our findings potentially impact the interpretation of the study. Assuming that 
cellular concentrations of p85 and NS1 are <1 mM, our results indicate that the conformational 
dynamics step is considered to be in pre-equilibrium. Under this condition, i.e., kex (= kf+kr) >> 
koff+kon[L], overall binding affinity of 1918 NS1 to iSH2
p85 is modulated by the population of 
the open conformation (i.e., binding-competent species) in the dynamic equilibrium step. This 
suggests that natural sequence variation in NS1 might affect the binding affinity to p85 in a 
noncanonical way. For example, any mutations in NS1, regardless whether they are located in 
the binding interface with iSH2p85, which affect the dynamic equilibrium can affect the binding 
affinity through an allosteric fashion. This can complicate the understanding of how NS1 
sequence variation affects the PI3K activation. This indicates the need to investigate the effects 
of sequence variation on the internal dynamics. 
Then, we sought to reveal whether other NS1 proteins also exhibit similar conformational 
dynamics in their free state. For this, we superimposed seven free NS1 structures from five IAV 
strains (H1N1, H3N2, H5N1, H6N6, and H12N5), and calculated their backbone RMSD relative 
to the NS1 structure of H1N1 (Fig.34B). Intriguingly, although all these NS1 proteins are in the 
free form, they exhibited varying degrees of RMSD in the iSH2p85-binding sites (Fig.34B). 
These regions with large RMSD also overlapped with the dynamic regions of free 1918 NS1 ED 
(Fig.31E). These structures collectively show the conformational fluctuation of NS1 ED proteins 
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captured in diverse crystallization conditions. Moreover, the residues in the hydrophobic cluster 
that underlies the conformational switch are highly conserved in IAVs (Fig.32D), indicating that 
the dynamics is a common feature of many NS1 proteins. This also suggests that molecular 
motion is of central importance to the understanding of the target recognition mechanisms of 
NS1 proteins of diverse IAV strains. 
 
 
Figure 34. The effects of sequence variation on the internal dynamics of NS1 ED. (A) The 
plot of measured kobs vs [iSH2
p85]. (B) The backbone RMSD of seven free NS1 structures from 
five IAV strains (H1N1, H3N2, H5N1, H6N6, and H12N5) relative to H1N1 NS1. 
 
In this study, we presented the molecular recognition mechanism by which 1918 NS1 ED 
binds to the p85 subunit of PI3K. Our results highlight the mechanistic role of the dynamic 
motion in the binding of NS1 to human p85. Recently, the crystal structure of PR8 NS1 
complexed with human TRIM25 was reported. Binding interface in NS1 ED for the coiled-coil 
domain of TRIM25 overlaps with that for iSH2p85. Therefore, it will be of interest to assess the 
extent to which the conformational dynamics of NS1 contributes to its interaction with TRIM25 
and other host proteins. Development of a ligand that interferes with the NS1 ED dynamics 
 86 
 
might lead to the development of highly effective anti-influenza therapeutics because the ligand 
will prevent binding of NS1 to both PI3K and TRIM25. 
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CHAPTER V 
STRUCTURE-GUIDED DESIGN OF A POTENT PEPTIDE INHIBITOR TARGETING THE 
INTERACTION BETWEEN CRK AND ABL KINASE* 
 
Background 
Inhibiting protein-protein interactions (PPIs) has emerged as an attractive strategy for 
overcoming drug resistance [194, 195]. However, binding interfaces of protein complexes are 
often suboptimal for the development of high-affinity inhibitors, because they are shallow and 
lack deep hydrophobic pockets. One such example is the SH3 domain [103]. While it plays 
critical roles as the “molecular Velcro” in numerous cellular signaling pathway [196], the SH3 
domain has proved to be a difficult target for drug development because of its weak affinity to 
cognate PRMs, with Kd ranging from 1 to 100 μM [197]. Despite recent advances [198, 199], the 
development of high-affinity SH3 ligands remains a challenge.  
CRK family proteins play important roles in cell proliferation and migration upon extra 
cellular stimuli [82]. The nSH3 of CRK recognizes the PRM of its binding partners, such as ABL 
kinase. A tyrosine at position 211 (Y211) of CRKII is the substrate of ABL kinase, as well as the 
BCR-ABL fusion protein [200-202]. The fusion of BCR and ABL, which constitutively activates 
ABL kinase, is found in ~90% of patients with CML [118]. Hence, phosphorylation levels of 
CRK proteins are considered to be a marker for BCR-ABL activity in CML patients [116, 203]. 
Recent studies has also shown the importance of ABL-CRK interactions in understanding the 
                                                 
* Reproduced with permission from “Structure-guided design of a potent peptide inhibitor targeting the interaction 
between CRK and ABL kinase” by Qingliang Shen, Veer S. Bhatt, Inna Krieger, James C. Sacchettinia and Jae-
Hyun Cho. 2018. Med. Chem. Commun. 9, 519-524. Copyright © 2018 The Royal Society of Chemistry. 
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effects of tyrosine kinase inhibitors, such as imatinib or dasatinib [200, 201].  
The interaction between ABL/BCR-ABL and CRK also plays important roles in bacterial 
and viral infections [59, 149]. Study by Burton showed that the ABL-CRK binding and 
subsequent CRK phosphorylation is required for the internalization of bacterial pathogen, such 
as Shigella flexneri [204]. It was also shown by Hrincius that the modulation of ABL-CRK 
interaction by NS1 play an important role in IAVs infection.   
The interaction between ABL or BCR-ABL kinase with CRK (ABL-CRK interaction) is 
mediated by the binding between the nSH3 domain of CRK and PRMs in ABL [205]. Our 
previous study has shown that ABL contains three PRMs that are recognized by the nSH3 
domain of CRKII [107]. Upon the nSH3CRK-PRMABL binding, the ABL kinase domain 
phosphorylates CRKII, which in turn transactivates ABL kinase activity (Fig.35) [123, 206]. 
Hence, the phosphorylation level of CRK proteins is considered to be a marker for BCR-ABL 
activity in CML patients [116, 203].  
 
 
Figure 35. The schematic diagram showing the interaction between CRKII and ABL 
kinase. The PRMs in the C-terminal of ABL kinase binds to nSH3 domain of CRKII. The kinase 
domain of ABL phosphorylates Y221 of CRKII upon the binding.  
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Imatinib targets the active site of the kinase domains in ABL and BCR-ABL and 
dramatically improves survival rates of CML patients [207]. However, more than 90 mutations 
in the ABL kinase domain were found to induce imatinib resistance [208]. Despite the 
development of second-generation inhibitors, drug resistance produced by certain mutations such 
as the T315I mutation, remains a major problem [209]. T315I gatekeeper mutation in the ATP 
binding site, which prevents the entry of imatinib to the active site, is one of the most frequent 
drug resistance mutation [210]. Hence, it is highly necessary to develop new approach to 
overcome drug resistance.   
In this chapter, we report here the structure-guided design of nM affinity peptide-
inhibitor for the nSH3 domain of CRKII. Because this inhibitor does not bind to ABL but binds 
its substrate CRK, it effectively inhibits phosphorylation of CRKII by wile type and T315I 
mutant ABL kinase. The work has been published in Medicinal Chemistry Communications. 
 
Experimental procedures 
Materials 
All protein samples for crystallization, fluorescence and NMR experiments, were prepared 
as described in Chapter II. Wild type and T315I ABL kinase were purchased from ProQinase. 
Recombinant human CRKII was expressed in E.coli and purified as described in Chapter II. 
Synthetic peptides were purchased in a crude form, and further purified using reverse-phase high 
performance liquid chromatography in our laboratory. The N- and C-termini of peptides were 
acetylated and amidated, respectively. The peptide concentration was determined by measuring 
the UV absorption at 280 nm of a single tyrosine at the C-terminal end of the peptides. 
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Crystallization and structure determination  
Crystallization conditions were screened using several commercial (Hampton Research) 
and in house screens. The protein as well as the PRM-2 were prepared in buffer G. The best 
crystals were obtained from 0.2 M lithium sulfate monohydrate, 0.1 M BIS-TRIS pH 5.5, 35% 
w/v PEG 3350. These crystals diffracted to 1.8 Å resolution in the space group P212121 and had 
one nSH3-ligand complex in the asymmetric unit. A 1.8 Å resolution data set was collected at 
113 K using an R-AXIS IV imaging-plate detector and Cu Kα radiation generated by a rotating-
anode X-ray generator (Rigaku–MSC). The data were processed using HKL2000 [208] in the 
same space group with cell dimensions of a = 27.6 Å, b = 41.3 Å and c = 56.8 Å. Molecular 
replacement in Phaser [211] using 1cka as the search model could output a unique solution in the 
same space group with one copy of the protein in the asymmetric unit. The solution was 
subjected to an initial cycle of model building using AutoBuild module of PHENIX[126] 
following which several iterations of manual model building in COOT[127] and refinement in 
REFMAC[139] were carried out. PRM-2 was added to the model guided by the Fo-Fc map. 
Water molecules were added after one more round of real and reciprocal space refinement. The 
final structure has R/Rfree = 17%/21%. The electrostatic potential surface of nSH3 domain was 
calculated using APBS and PDB2PQR [128-130]. 
 
NMR spectroscopy  
NMR HSQC spectrum was acquired using a protein sample in 20 mM sodium phosphate 
(pH 6.1), 80 mM NaCl, 0.02% sodium azide, 1 mM EDTA, 10 μM DSS (4,4-dimethyl-4-
silapentane-sulfonate), and 10% D2O at 25 C. The NMR experiment was performed on Bruker 
Avance 600 MHz spectrometers equipped with a cryogenic probe. NMR spectra were processed 
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with NMRPipe[131] and analyzed with NMRViewJ (One Moon Scientific, Inc.). The temperatures 
of NMR sample were calibrated using the deuterated methanol-d4 [162]. 
 
Fluorescence binding assay  
The dissociation constants (Kd) of nSH3-PRM complexes were measured by monitoring 
the change of tryptophan fluorescence signal. Excitation wavelength was 295 nm. All binding 
assays were performed in a stirred 1-cm path length cuvette using a PTI QM-400 fluorimeter. 
Protein concentration used for the fluorescence-based binding assays was 0.1 μM. The 
measurements were done in 20 mM sodium phosphate (pH 6.1) and 80 mM NaCl at 25 C. The 
Kd was calculated by assuming a 1:1 complex, and by the global fitting of the repeatedly 
measured fluorescence intensities to the eq. 4. The reported Kd values are the average of 2 
repeated measurements. The Kd values of nSH3-PRM-3 were measured at 30, 35, and 37 C. The 
binding free energy, Gbind, was calculated using 𝛥𝐺𝑏𝑖𝑛𝑑 = −𝑅𝑇 ln(1/𝐾𝑑). The Gbind at 298 K 
was calculated by a linear fitting of the data. The uncertainty of the Gbind (298 K) was estimated 
by 95% confidence intervals of the linear regression curve.    
 
CRK-phosphorylation assay  
2 M of CRKII (residues 1 – 304) was incubated with 5 nM recombinant human wild 
type ABL kinase (ProQinase, residues 118 – 535) in 20 m M Tris (pH 7.6), 50mM NaCl, 2 mM 
DTT, 2 mM MgCl2, 100 M ATP at 25 C. The reaction conditions for T315I ABL kinase were 
the same except that the concentration of T315I ABL kinase was 25 nM. The specific activity of 
T315I ABL was 10-fold lower than that of wild type ABL. The phosphorylation reaction was 
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stopped by adding 15 mM EDTA. The phosphorylated and non-phosphorylated CRKII were 
separated by running a native polyacrylamide gel electrophoresis (12%). Thermo Scientific 
Pierce Silver Statin kit was used for detection of protein bands. The band intensity was measured 
by ImageJ [212]. It should also be noted that the inhibitory activity of PRM-3 depends on the 
concentration of CRKII used in the assay since PRM-3 binds to CRKII, which is a substrate of 
ABL kinase. This rules out using IC50 as an indicator for inhibitor activity because the IC50 value 
changes depending on the concentration of CRKII used in the in vitro assay. Instead, comparison 
with imatinib provides an alternative way to assess the inhibitory activity of PRM-3 on ABL-
dependent CRK phosphorylation. 
 
Results 
The development of high affinity peptide binder to nSH3 of CRKII 
We selected PRM-1 as a starting molecule for the optimization of binding affinity to the 
nSH3CRKII domain. The primary structure of PRM-1 was derived from C3G, which is one of the 
cellular binding partners of CRKII [87]. The Kd of the nSH3-PRM-1 was reported to be 1.9 μM 
[106], and its high resolution crystal structure (PDB ID: 1CKA) was available for structure-based 
optimization [106]. Previous studies indicate that the nSH3 domain of CRKII recognizes the core 
PxΦPxK sequence in PRMs, where Φ and x represent hydrophobic and any amino acids, 
respectively [106, 107, 202]. To describe the sequence of peptides used in this study, we adopted 
the notation proposed by Lim et al., where Φ in the core sequence, PxΦPxK, is designated as X0 
position (Table 8) [105]. The residues located at the C-terminal end of X0 are designated as X-1, 
X-2, etc. The residues located at the N-terminal end of X0 are designated as X1, X2, etc.  
 
 93 
 
Table 8. Binding affinities of PRMs to the nSH3 domain 
aRef. [106] 
bThe asymmetric uncertainty was estimated from 95% confidence band of the linear regression 
curve. 
 
The crystal structure of the nSH3-PRM-1 complex showed that the N- and C-termini of 
PRM-1 are flexible owing to lack of favorable interactions with the nSH3 domain [106]. To 
improve the interactions in the terminal regions of PRM-1, we designed PRM-2 with following 
modifications: First, the sequence was extended by adding three residues to the both N- and C-
termini of PRM-1. The added residues were derived from the C3G sequence (residues 279 – 281) 
(Table 8). Second, P-2 in PRM-1 was replaced by K in PRM-2 to increase long-range 
electrostatics as suggested by our previous study[6]. The structure of the nSH3-PRM-1 complex 
shows that the side chain of P-2 does not directly contact the nSH3, instead pointing away from 
the complex interface. Third, a Y-7 was incorporated into the C-terminus for the spectroscopic 
quantitation of the peptide. Using the fluorescence change of W169 in the nSH3 domain upon 
binding to PRM-2, the Kd of the nSH3-PRM-2 complex was measured to be around 0.4 μM, 
which is 4-fold higher than that of PRM-1 (Fig.36A).  
 
 
PRMs 
Sequences 
Kd (M) (uncertainty) 
7 6 5 4 3 2 1 0 -1 -2 -3 -4 -5 -6 -7 -8 -9 
PRM-1    P P P A L P P K K R     1.9a 
PRM-2 D N S P P P A L P K K R Q S Y   0.4 (+0.1, -0.1) 
PRM-3    S P P A L P K K R Q S Y R R 0.009 (+0.008, -0.004)b 
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Figure 36. Fluorescence-based binding affinity measurements. (A) Binding isotherm of 
PRM-2 and the nSH3 domain. (B) Temperature-dependent binding free energy, ΔGbind, of the 
nSH3-PRM-3 complex. The solid line represents the best linear fit to the corresponding data 
points. The dotted lines represent 95% confidence band of the linear regression curve.  
 
To reveal the binding mode of PRM-2, we determined a high-resolution (1.77 Å) crystal 
structure for the nSH3-PRM-2 complex (PDB ID: 5L23) (Fig.37A, Table 9 and Fig.A11, 
Appendix II). The structure of core sequence (PxLPxK) adopts a PPII helix and is virtually 
identical between PRM-1 and PRM-2 (Fig.37B and Fig.A12, Appendix II). The three N-terminal 
residues in PRM-2 forms an extended conformation without intermolecular interactions with the 
nSH3 domain. In contrast, the modified C-terminal residues (R-4-Q-5-S-6-Y-7) of PRM-2 showed 
a novel binding mode. The Ψ angle (-38.6) of R-4 deviates significantly from that of the PPII 
helix (~150) (Fig. 37C). Moreover, the aromatic side chain of the C-terminal Y-7 is sandwiched 
between the backbone of PRM-2 and the binding surface of the nSH3 domain (Fig. 37D). The 
side chain hydroxyl group of Y-7 is hydrogen bonded (2.5 Å) to the side chain carboxyl group of 
E166 of nSH3 domain, stabilizing the C-terminal residues of PRM-2. This binding mode has not 
been observed in the nSH3-PRM complexes. 
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Figure 37. Structural analysis of the nSH3-PRM-2 complex. (A) Crystal structure showing 
the binding mode of PRM-2. (B) Structural comparison of PRM-1 (PDB ID: 1CKA) and PRM-2 
(PDB ID: 5L23) bound to the nSH3 domain. The ligands shown in magenta and green represent 
the PRM-1 and PRM-2, respectively. For clarity, only the residues involved in key 
intermolecular interactions are shown in stick model. (C) Binding mode of the C-terminal R-4-Q-
5-S-6-Y-7 moiety of PRM-2. The arrow represents the breakage of PPII helix conformation at R-4. 
(D) The interaction between Y-7 of PRM-2 and E166 of the nSH3 domain. For clarity, sidechains 
of other residues are omitted. (E) Electrostatic potential surface of the nSH3 domain. PRM-2 is 
shown in green color. 
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Table 9. Data collection and refinement statistics  
of the crystal structure of the nSH3-PRM-2  
complex. 
 
 5L23.PDB 
Data Collection  
space group P212121 
Cell  dimensions  
     a, b, c (Å) 27.6, 41.3, 56.8 
     α, β, γ (⁰) 90.0, 94.3, 90.0 
resolution (Å) 24.83-1.77 (1.87-1.77)a 
Rmerge  16% (20%) 
completeness (%) 100 (99.9) 
I / I 11.7 (8.4) 
Redundancy  7.4 (7.2) 
  
Refinement  
resolution (Å) 24.83-1.77 
number of reflections  6462 
Rfactor
a 0.17 
Rfree
a 0.21 
number of protein 
atoms  
509 
number of water 
atoms 
99 
number of ligand 
atoms 
126 
average B-factors  
  protein chain (Å2) 12.60 
  ligand chain(Å2) 13.43 
  water molecules (Å2) 25.30 
aRfactor = ∑|Fobs-Fcalc|/∑|F|obs, where Rfree refers to the  
Rfactor for 3% of the data that were excluded from the  
refinement 
 
We have discovered that the PRM of NS1 of IAV binds to the nSH3 domain with a 
nanomolar affinity [6]. This high binding affinity is owing to that positively charged residues in 
the C-terminal region of the viral PRM mediates long-range, non-specific electrostatic 
interactions with the large negatively charged surface of the nSH3 domain [6]. The structure of 
the nSH3-PRM-2 complex also indicated that addition of positively charged residues at the C-
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terminus of PRM-2 would enhance long-range electrostatic interactions (Fig.37E). Based on the 
hypothesis, we designed PRM-3 (Table 8) by adding two Arg residues to the C-terminus of 
PRM-2. In addition, three N-terminal residues of PRM-2 were removed in PRM-3 because our 
crystal structure indicated that these residues lack favorable interactions with the nSH3 domain 
(Fig.37A and Fig. A12, Appendix II).  
Remarkably, the binding affinity of PRM-3 to the nSH3 domain was too high to reliably 
measure it at 25°C using intrinsic Trp fluorescence change. Therefore, we measured Kd values at 
three different higher temperatures and estimated the Kd at 25°C using linear extrapolation of the 
temperature-dependent binding free energy (Fig.36B and Fig.A13, Appendix II). This yielded a 
Kd of ~9 nM at 25°C. This is about 200-fold higher in affinity than the one of PRM-1. Despite 
the large difference in Kd, NMR chemical shift perturbation analysis indicated that PRM-3 binds 
to the same site in the nSH3 domain as PRM-1 and PRM-2 (Fig.38C).  
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Figure 38. Structural analysis of the nSH3-PRM-3 complex. (A) Overlaid 1H-15N HSQC 
spectra of the free nSH3 (black) and nSH3-PRM-3 (red) complex. The residues whose chemical 
shifts change significantly are labeled. (B) NMR chemical shift perturbation of the nSH3 domain 
induced by binding of PRM-3. (C) Binding interface of the PRM-3 probed by the NMR CSP 
analysis. For comparison of binding interface, PRM-2 is shown in green. The residues whose 
backbone chemical shifts are significant (larger than average + 1 standard deviation) and modest 
(larger than average but less than average + 1 standard deviation) are shown in magenta and 
orange, respectively.     
 
Long range electrostatics play a critical role in the tight binding of PRM-3 to nSH3 
To determine whether the increased binding affinity is due to enhanced long-range 
electrostatic interactions, we compared the Kd value of the nSH3-PRM-3 complex in the 
 99 
 
presence of 80 mM NaCl with that in the presence of 1M NaCl (Fig.A13D, Appendix II). The 
Debye screening lengths are 10.7 Å and 3.0 Å in the presence of 80 mM and 1M NaCl, 
respectively. Hence, long-range electrostatic interactions are screened in a high-ionic strength 
solution, while the short-range electrostatic interactions within 3.0 Å remain effective under the 
same conditions. We observed that the Kd value of the nSH3-PRM-3 complex increased by 50-
fold in the presence of 1M NaCl compared to the one in the presence of 80 mM NaCl 
(Fig.A13D, Appendix II). This result shows that the high binding affinity of PRM-3 is largely 
due to the enhanced long-range electrostatic interactions with the nSH3 domain. The role of 
long-range electrostatic interactions in increasing binding affinity was also demonstrated in 
diverse protein-protein/ligand interaction [6, 144, 147, 148, 213, 214]. 
To examine the uniqueness of the PRM-3 sequence, we searched its sequence in known 
human proteome using ScanProsite [215], in which the search query was ‘P-x-x-P-x-K-K-R-Q-
S-Y-R-R’, where x represents any amino acids. Interestingly, the search did not find a match to 
the sequence of PRM-3. The search without the last three modified amino acids (YRR) retrieved 
C3G as the closest match. Although this does not directly indicate the selectivity of PRM-3 to 
the nSH3 of CRKII, its unique sequence would be beneficial for reducing off-target effects in a 
cellular environment. Further cell-based selectivity tests will be conducted in our laboratory.   
 
The inhibitory effect of PRM-3 on the ABL-dependent phosphorylation of CRKII 
The interaction between the nSH3CRK and PRMABL is a prerequisite step for ABL-
dependent phosphorylation of CRKII at Y221 (Fig.35)[202, 216]. Thus, we tested the inhibitory 
activity of PRM-3 on ABL-dependent CRKII phosphorylation using an in vitro assay with 
purified proteins. The inhibition assay is based on the separation of CRKII and CRKII-pY221 
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(phosphorylated CRKII) using a native-gel electrophoresis (PAGE). Upon phosphorylation, 
CRKII undergoes a large-scale conformational change resulting in differential migration between 
CRKII and CRKII-pY221 during a native gel electrophoresis (Fig.39A and 39B and Fig.A14, 
Appendix II) [217]. 
 
 
Figure 39. ABL-dependent CRK phosphorylation assay. Time-dependent phosphorylation of 
CRKII using (A) wild type and (B) T315 ABL kinase in the absence (control) and presence of 
PRM-3 or imatinib. Plot of CRK phosphorylation levels by (C) wild type and (D) T315I ABL 
kinase as a function of reaction time. Black circles represent the control. Blue and red circles 
represent the results in the presence of imatinib and PRM-3, respectively 
 
The assay showed that wild type ABL kinase phosphorylated approximately 62% and 
21% of CRKII in the absence and presence of 1 µM PRM-3, respectively (Fig.39A and 39C). 
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Interestingly, CRK-phosphorylation level was ~33% in the presence of 1 µM imatinib under the 
same experimental conditions. This result shows that PRM-3 is a potent inhibitor for PPIs 
between CRKII and ABL. Moreover, PRM-3 showed strong inhibition of CRK phosphorylation 
by T315I gatekeeper mutant of ABL kinase (Fig.39B and 39D), whereas imatinib was ineffective 
under the same conditions. Mutations at the gatekeeper residues (T315I/M) have proven highly 
resistant to most of drugs including imatinib and all second-generation tyrosine kinase inhibitors. 
Ponatinib is the only currently approved inhibitor effective to the gatekeeper mutants [218]. 
However, emergence of compound mutations that confer resistance to Ponatinib was reported in 
preclinical studies [219].  
To overcome drug resistance, it is highly desirable to develop inhibitors, of which 
working mechanisms do not overlap with those of existing inhibitors. Our results highlight the 
fundamental difference in the working mechanisms of imatinib and PRM-3: while imatinib binds 
to the active site of ABL/BCR-ABL, PRM-3 binds to CRK, which is a substrate of ABL/BCR-
ABL. Therefore, it is likely that PRM-3 will also be effective for other kinase domain mutants of 
ABL or BCR-ABL although further investigations using cell-based assay are needed. 
 
Discussion 
In this chapter, following structure-guided optimization, we developed a highly potent 
peptide inhibitor, PRM-3, for the interaction between CRKII and ABL kinase. PRM-3 binds to 
the nSH3 domain with Kd of 9 nM which is 200-fold higher in affinity to the nSH3 domain than 
that of the starting molecule, PRM-1. We showed that the high affinity of PRM-3 is due to 
enhanced long-range electrostatic interactions, which also substantiates our previous finding 
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regarding the role of non-specific, long-range electrostatic interactions in ligand-binding affinity 
to the nSH3 domain.  
The mechanistic insights gained during the optimization of PRM-3 will facilitate the 
design of more potent and selective inhibitors for the CRK-mediated protein-protein interactions. 
The inhibitors will be of significance because the expression levels of CRK proteins are 
correlated with aggressive and malignant behaviors in cancer cells [83, 109, 220]. Here, we 
showed that PRM-3 has a high inhibitory activity against ABL-dependent CRK-phosphorylation, 
which is considered to be a readout for BCR-ABL activity in cancer cells. Further studies 
elucidating the cellular efficacy and toxicity of PRM-3 are in progress. 
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CHAPTER VI 
SUMMARY AND FUTURE DIRECTIONS 
 
Molecular recognition between biomolecules plays a central role in virtually all 
biological processes including transcription, translation, and signaling pathways [221]. Studies 
on the structure and dynamics of biomolecules are important for elucidating the mechanisms of 
molecular recognition at atomic resolution.  
Viruses are obligate intracellular parasites that have extensive interactions with host 
proteins. Throughout the infection cycle, viral proteins hijack host factors and interfere with host 
cell regulation such as antiviral immune responses. Despite its importance, the molecular basis 
by which viral proteins interact with diverse host proteins is still not well-understood. The 
purpose of this Dissertation is to determine the molecular recognition mechanisms by which NS1 
of 1918 IAV hijacks two host proteins CRK and PI3K. The results presented in this Dissertation 
contributes to the understanding of the mechanisms and provides insights into the fundamental 
role of protein dynamics in molecular recognition mechanisms.   
In Chapter 2, the crystal structure of the nSH3CRKII in complex with the 1918 PRMNS1 
was determined. The binding thermodynamics and kinetics were determined using fluorescence 
spectroscopy and NMR relaxation dispersion. This study showed that the 1918 PRMNS1 binds to 
the nSH3CRK with an exceptionally high affinity with 3000-fold lower Kd and 100-fold faster kon 
compared to those for the interaction between CRK and PRMJNK1. The contribution of long-
range electrostatics in binding kinetics was demonstrated by the linear dependence of log kon on 
the net charge of PRMs. This result suggested that the rapid and tight binding provides 1918 NS1 
with an advantage to compete with host signaling proteins.  
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In Chapter 3, molecular basis of the interplay between structural disorder of the 1918 
PRMNS1 and its long-range electrostatic interactions with the nSH3CRKII was studied. Using X-
ray crystallography and NMR spectroscopy, it was shown that the 1918 PRMNS1 retains 
substantial conformational flexibility in the nSH3-bound state. MD simulations showed that 
structural disorder of the bound PRM increases the number of electrostatic contacts and 
decreases the mean distances between the positively charged residues in the PRMNS1 and the 
acidic residues in the nSH3CRK. These results provided an insight into the role of a 
polyelectrostatic interaction in the molecular recognition for a high-affinity fuzzy complex. 
In Chapter 4, the molecular recognition mechanism between the 1918 NS1 ED and 
iSH2p85 was determined using a combined approach including NMR relaxation dispersion, X-
ray crystallography, and small-angle X-ray scattering. Structures of the 1918 NS1 ED and its 
complex with the iSH2p85 were determined using NMR spectroscopy and X-ray crystallography, 
respectively. NMR relaxation dispersion experiments revealed that the free 1918 NS1 ED 
undergoes a dynamic conformational switch in the sub-ms timescale between the closed (p85-
binding-incompetent) and the open (p85-binding-competent) states. Combined with kinetic 
analysis, it was shown that binding of 1918 NS1 ED and iSH2p85 follows conformational 
selection binding mechanism, in which the dynamic motion of free 1918 NS1 ED controls the 
overall binding process. Moreover, comparison of NS1 ED structures of diverse IAV strains 
indicated that the structural adaption occurring through a dynamic conformational exchange 
might be a common mechanism among NS1 proteins.  
In Chapter 5, a peptide inhibitor was developed targeting the interaction of CRK with 
ABL kinase. The peptide inhibitor was developed based on the mechanism by which the 1918 
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PRMNS1 tightly binds to the nSH3CRK, which was demonstrated in Chapters 2 and 3. An in vitro 
assay showed that the inhibitor inhibits the ABL-dependent phosphorylation of CRK more 
effectively than imatinib. Moreover, the PRM peptide also inhibited the CRK phosphorylation by 
T315I-ABL kinase, which is resistant to all first- and second-generation tyrosine kinase 
inhibitors. This study provided a promising alternative approach to overcome the drug resistance 
of ABL kinase. 
The studies presented in this dissertation demonstrate how 1918 NS1 interacts with CRK 
and PI3K, respectively. However, the mechanism of the ternary interaction among 1918 NS1, 
CRK, and PI3K remains unknown. Hence, we will use an integrative structural biology approach 
including NMR spectroscopy, X-ray crystallography, SAXS to get high-resolution structural 
information of the ternary complex.  
Due to the structural dynamics of the CTT, 1918 NS1 may form a “fuzzy complex” with 
CRK. Therefore, obtaining a high-resolution crystal structure of the ternary complex, especially 
in the dynamic region, may be difficult. NMR is highly complementary to X-ray crystallography 
to investigate the structure and dynamics of the ternary complex [222]. Especially, NMR 
Paramagnetic relaxation enhancement (PRE) is a powerful method to probe the transient protein-
protein interactions [223]. The NMR studies of large protein complexes are limited by line 
broadening and low signal-to-noise ratio [224]. To increase the resolution and sensitivity, the 
methyl-labeling approach combined with methyl-TROSY will be used [225-227]. Transferred 
NOESY and PRE technique will be combined to characterize the large protein systems [222]. In 
addition, SAXS has been widely used for the quantitative analysis of flexible system, and it 
provides low-resolution information of the conformation of protein complexes [228]. Hence, we 
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will integrate NMR, SAXS and X-ray crystallography to study this dynamic protein complex 
[229].  
In addition, a PRM-derived peptide inhibitor was designed to inhibit the oncogenic CRK-
ABL interaction. However, the development of peptide-based drugs is often limited by their poor 
plasma half-life and cell permeability. Recently, a proteolysis targeting chimera (PROTAC) has 
emerged as a powerful therapeutic strategy to address diseases that are driven by the aberrant 
overexpression of a protein [230, 231]. PROTAC molecules are two-headed molecules that are 
capable of simultaneously binding E3-ubiquitin ligase and a target protein. PROTAC molecules 
recruit E3 ligase to the proximity of a target protein, resulting in its proteolytic degradation. It 
has been found that CRK is overexpressed in several human cancers, and the knockdown of 
CRK significantly decreases the malignant and metastatic features of these cancers [232]. 
Therefore, it will be of interest to examine the CRK-degradation efficacy induced by a PROTAC 
molecule in which the PRM inhibitor is linked to E3 ligase ligand lenalidomide (Fig.40). Hence, 
we will first develop high affinity peptides targeting CRK by optimizing their net charges (Fig. 
A5). The lenalidomide will be conjugated to the peptide via a PEG linker [233]. The efficacy of 
the PROTAC molecules will be tested using human cancer cell lines [83]. The degradation of 
CRK will be detected by anti-CRK antibodies.  
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Figure 40. A schematic diagram showing the design of PROTAC molecules. The 
bifunctional PROTAC molecules simultaneously recruit CRK and the E3-ubiquitin ligase. E2 
ubiquitin-conjugating enzyme, which associates with E3-ubiquitin ligase, ubiquitinates CRK 
upon binding to CRK-PROTAC-E3 ternary complex and induces the degradation of CRK by 
proteasome.  
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APPENDIX I 
Table A1. The PDB IDs of human SH3-ligand complexes in which K of a ligand and  
acidic residues of SH3 domain form salt-bridges. 
 
PDB 
ID 
Ligand sequence Acidic residues forming salt-bridge with K of 
bound ligand 
5UL6 YGRPPLPPKQKRK (NS1) D147 (2.8 Å), E149 (2.8 Å), D150 (2.8 Å) 
5IH2a YEKPALPRKR D147 (3.0 Å), E149 (2.8 Å), D150 (2.7 Å) 
1CKAa PPPALPPKK D147 (2.8 Å), E149 (2.7 Å), D150 (2.7 Å) 
4F14 PPPTLPKPKLP D969 (3.5 Å), D971 (2.5 Å), E972 (2.7 Å) 
1H3H APSIDRSTKPA E31(2.9 Å) 
2J6F PPKPRPRR D16 (3.0 Å), E16 (2.5 Å) 
2RQU CIISAMPTKSSRKAKKPAQ E1085 (2.8 – 12.5 Å)b 
2VWF IQPPPVNRNLKPDR E13 (2.9 Å), E16 (2.8 Å) 
2W0Z APPPRPPKP E16 (2.8 Å) 
4LN2 LAPPKPPLPE E885 (2.9 Å) 
5IXF AKPPVVDRSLKPGA E224 (2.7 – 12.2 Å)b 
a These are the nSH3 domain of mouse CRKII. The amino acid sequences of the nSH3  
domain of mouse and human CRKII are the same. 
b These represent the shortest and longest distances among the NMR ensemble structures. 
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Table A2. The results of CPMG-RD data fitting of individual residues. 
 
Residues kex (s
-1) 
PRMNS1 PRMJNK1 
146 953.9  32.3 -a 
148 -a 2558.3  448.2 
149 847.2  46.1 2427.1  80.1 
150 1094.3  39.7 2343.5  80.6 
163 817.3  56.4 -a 
164 874.7  95.2 2316.1  346.7 
166 904.8  30.9 2999.8  330.1 
167 775.4  95.3 -a 
169 1017.3  33.1 2452.8  84.2 
186 600.1  38.5 -a 
187 735.2  56.4 -a 
169 indole amide 820.8  108.5 -a 
a These are not analyzed because either no-dispersion (Rex < 2 s
-1) was 
observed or peaks overlap with other peaks. 
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Table.A3-1. The difference in average pairwise distances. 
Residues 
in 
PRMNS1 
Difference in average pairwise distances (MDa - Crystalb) (Å) 
Acidic residues in nSH3 domain 
D142 D147 E149 D150 D163 E166 
R211 0.0 -c -c -c -c -c 
K219 -c 1.5 1.3 0.5 -0.2 0.7 
R220 -c -1.4 -1.3 -2.6 -5.4 -5.4 
K221 -c -1.3 1.8 -0.0 2.6 -0.5 
aMD trajectories of PRMNS1A 
bCrystal structure of PRMNS1A (PDB ID: 5UL6) 
cThese distances were longer than 15 Å and not included in the analysis. 
 
 
 
 
Table.A3-2 The difference in average pairwise distances.  
Residues 
in 
PRMNS1 
Difference in average pairwise distances (MDa - Crystalb) (Å) 
Acidic residues in nSH3 domain 
D142 D147 E149 D150 D163 E166 
R211 -1.7 -c -c -c -c -c 
K219 -c -6.1 -4.0 -4.9 1.9 -1.6 
R220 -c -0.6 0.5 1.1 3.2 0.9 
K221 -c -5.6 -3.6 -3.0 5.0 -0.3 
aMD trajectories of PRMNS1B 
bCrystal structure of PRMNS1B (PDB ID: 6ATV) 
cThese distances were longer than 15 Å and not included in the analysis. 
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Table.A4 The residues in the between 1918 NS1 ED and iSH2p85β. 
 Interface Residues 
1918 NS1 
ED 
A86, S87, R88, Y89, L90, T91, M93, L95, E96, E97, M98, S99, R100, 
D101, W102, C116, R118, N133, F134, S135, E142, T143, L144, I145, 
L146, R148, E159, S161, P162, L163, P164, S165 
iSH2p85β 
H444, M562, R565, K566, I567, R568, D569, Q570, L572, V573, W574, 
T576, Q577, K578, A580, R581, N582, K583, I585, N586, L589, I591 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 138 
 
 
Table.A5 Summary of the binding affinities between PRM-derived peptides and nSH3 of 
CRK 
PRMs 
Sequences 
Kd (M) (uncertainty) 
 5 4 3 2 1 0 -1 -2 -3 -4 -5 -6 -7 -8  
PRMNS1  Y G R P P L P P K Q K R K   0.094 (+0.007, -0.007) 
PRM-4  Y P P P P L P P K R R R R R  0.023 (+0.002, -0.002) 
PRM-5  C P P P P L P R K R R R R R  0.048 (+0.010, -0.010) 
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APPENDIX II 
 
 
Figure A1. (A) NMR 15N CPMG-RD profiles of the nSH3 domain, which is mixed with 
PRMNS1. Based on the Kd, the population of the nSH3-PRM
NS1 complex is estimated to be ~93 
% of the entire population of nSH3 domain. The residue numbers are shown in each figure. The 
blue and red circles represent the data acquired at 14.1 T and 18.8 T, respectively. The solid lines 
represent the best fit to the individual residues. The results of individual fit (kex values) are 
shown in Table A2, Appendix I. (B) The positions of 15N atoms whose CPMG-RD profiles were 
analyzed are shown as sphere model in the structure of nSH3-PRMNS1 complex. 
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Figure A2. (A) NMR 15N CPMG-RD profiles of the nSH3 domain, which is mixed with 
PRMJNK1. Based on the Kd, the population of the nSH3-PRM
JNK1 complex is estimated to be ~93 
% of the entire population of nSH3 domain. The residue numbers are shown in each figure. The 
blue and red circles represent the data acquired at 14.1 T and 18.8 T, respectively. The solid lines 
represent the best fit to the individual residues. The results of individual fit (kex values) are 
shown in Table A2, Appendix I. (B) The positions of 15N atoms whose CPMG-RD profiles were 
analyzed are shown as sphere model in the structure of nSH3-PRMNS1 complex (Note: the 
structure of nSH3-PRMJNK1 is not available). 
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Figure A3. An overlay of temperature-dependent chemical shift changes for the C-terminal 
positively charged residues (K217, K219, R220 and K221) in PRMNS1.  
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Figure A4. 15N-edited NOESY-HSQC of the C-terminal positively charged residues (K219, 
R220, and K221) in PRMNS1 bound to the nSH3 domain. The data was acquired using a 
sample of 15N-labeled PRMNS1 saturated by non-labeled nSH3 domain. The NOESY mixing time 
was 100 ms.  
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Figure A5. (A) {1H}-15N heteronuclear NOE and (B) 15N R2 of the nSH3 domain saturated by 
PRMNS1. Red bars represent the residues in the nSH3 domain that are in the binding interface 
with PRMNS1. This represents that the elevated R2 in PRM
NS1 is not induced by its on-off 
process.  
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Figure A6. The binding affinity of 1918 NS1 ED-CTT-W187R and iSH2p85β was not 
affected by reversing the analyte and ligand. (A) iSH2p85β with His6 and SUMO tags was 
immobilized on biosensors, while a range of concentration (10, 25, 50, 75, 100 nM) of 1918 NS1 
ED-CTT-W187R were used as analytes kept in solution. (B) NS1 ED-CTT-W187R was 
immobilized on biosensor while iSH2p85β was in the well.  
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Figure A7. NMR HSQC spectra of NS1 ED of 1918 Spanish IAV recorded at 25 °C. 
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Figure A8. The residues in the interface of 1918 NS1 ED and iSH2p85β. The inferface residues 
on NS1 ED and iSH2p85β are shown in blue and orange spheres, respectively.  
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Figure A9. Overlaid structures of p85 in free state and in complex with 1918 NS1 ED. The 
free p85 (PDB ID: 3MTT) is represented as cartoon in cyan color. 1918 NS1 ED is shown as 
gray surface. Bound p85 is shown as cartoon in orange.  
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Figure A10. 1918 NS1 ED-iSH2p85 binding does not change the intrinsic fluorescence 
signal. The fluorescence emission spectra of free 1918 NS1 ED and iSH2p85 are shown in blue 
and green, respectively. Red curve represents the sum of the emission spectra of free 1918 NS1 
ED and iSH2p85 . The black dots represents the emission spectrum of the complex of 1918 NS1 
ED and iSH2p85. 
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Figure A11. Crystal structure of the nSH3-PRM-2 complex. Representation of the 2FO-FC 
electron map of PRM-2 contoured at 1.  
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Figure A12. Schematic diagrams of the intermolecular interactions between the nSH3 domain 
and (A) PRM-1 and (B) PRM-2. Polar interactions are depicted as dotted lines. These figures 
were prepared using LIGPLOT+ [234]. 
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Figure A13. Binding isotherms of the nSH3 and PRM-3 at (A) 30, (B) 35, and (C) 37 C in the 
presence of 80 mM NaCl, and (D) 35 C in the presence of 1M NaCl. The Kd values are average 
of two repeated measurements at each temperature.   
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Figure A14. Time-dependent phosphorylation of CRKII using (A) wild type and (B) T315I ABL 
kinase in the absence (control) and presence of PRM-3 or imatinib. The minor band below a 
major band is not an impurity but an alternative conformation separated during native PAGE. 
CRKII undergoes structural exchange between alternative conformations [217] The reported 
phosphorylation ratio is the average and standard deviation of four repeated assays. 
 
